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CHAPTER 1: INTRODUCTION 
Conventional imaging modalities, such as radiography, ultrasound, computed 
tomography (CT), and magnetic resonance imaging (MRI) have been used for years to 
identify and characterize many diseases, including cancer, based on anatomic 
differences in tissue density, their shape, size, and water content(1). Recently, with the 
advent of functional imaging modalities, clinicians have been able to characterize 
diseases based on changes at the molecular level(1). Positron emission tomography 
(PET) imaging is used clinically and for translational research to study these molecular 
mechanisms. In the clinic, PET has shown utility in diagnosing and staging cancer, 
assisting in radiotherapy treatment planning, and monitoring chemotherapy(2). 
Preclinically, PET has been used in small animal research where new molecular probes 
are employed to target, detect, and visualize processes associated with cancer.  
1.1 Overview of Positron Emission Tomography (PET) 
PET is a non-invasive imaging modality where a small mass of radioactive tracer 
is injected into the patient, and through a series of reconstruction algorithms, an image 
portraying specific tissue uptake of the tracer is displayed. First, a probe (a small 
molecule, antibody, or peptide) with an affinity for the molecular target is labeled with a 
positron emitting radioisotope. A table of common isotopes and their half-lives can be 
found in Table 1. Matching the physical and biological half-lives of the PET nuclide and 
the target probe, respectively, ensures that the probe accumulates in the tumor before 
the radioactivity decays and allows clearance from normal tissues. In this regard, 




– is achieved.  
Isotope Half-Life 
O-15 122.24 s 
N-13 9.97 m 
C-11 20.4 m 
F-18 110 m 
Cu-64 12.7 h 
Y-86 14.72 h 
Br-76 16.2 h 
Ga-68 68.1 h 
Zr-89 78.4 h 
I-124 4.18 d 
Table 1. Possible PET radioisotopes and their half-lives. 
A patient is injected with the probe, and as the radionuclide decays it emits 
positrons that annihilate with electrons within the tissues producing two coincident 
photons that emit energy at 511 keV. Ring detectors made of scintillation crystals 
positioned around the subject pick up on the coincident photons and process their spatial 
location, energy, and arrival time, and through a series of reconstruction algorithms a final 





Figure 1. Principles of PET imaging. Upon decay, the radionuclide emits positrons that 
meet with electrons within the tissue that produces two gamma photons of 511 keV. This 
research was originally published in Angewandte Chemie Internaltional Edition. Philip W. 
Miller, Nicholas J. Long, Ramon Vilar, et al. Synthesis of 11C, 18F, 15O, and 13N 
Radiolabels for Positron Emission Tomography. 2008;47(47):36. 
 
Several tracers are currently approved by the Food and Drug Administration (FDA) 
which target metabolism, proliferation, hypoxia, but the most common PET probe for 
cancer is 18F-fludeoxyglucose (FDG). FDG is chemically known as 2-deoxy-2-(18F)fluoro-
D-glucose, which is an analog of glucose consumed by tissues in the body. Uptake of the 
tracer marks tissues scavenging for glucose, which is abundant in proliferating tumors. 
Since 2000, there has been a nine-fold increase in the number of FDG-PET scans 
performed in the U.S., possibly driven by the enhanced sensitivity and specificity of PET 
as compared to other imaging modalities(4). In 2011 it was estimated that 1.8 million 
FDG-PET scans were performed, with 94% of the scans for cancer patients(1). It is 
increasingly being used to assess therapeutic response and tumor biology, although a 
disadvantage is its background uptake in normal, high glucose-consuming tissues (brain, 




tracer. Additionally, FDG-PET is a non-specific tracer, and is unable to stratify patients 
who would benefit from a particular molecular treatment. Therefore, efforts have been 
made to develop tracers that target intracellular and cell-surface receptors that are 
uniquely expressed or overexpressed in cancer. In order to target these PET nuclides to 
receptors present on tumors, carriers in the form of small molecules, peptides, or 
antibodies must be linked to the nuclide and are employed to enhance the signal-to-noise 
ratio of the target to background uptake. 
The research described throughout this dissertation solely focuses on the use of 
antibody-based tracers. The following section was adapted in full with permission from 
the Journal of Labelled Compounds and Radiopharmaceuticals “89Zr-ImmunoPET 
companion diagnostics and their impact in clinical drug development” by Brooke N. 
McKnight and Nerissa T. Viola-Villegas, volume 61, issue 9(5).  
1.1.1 ImmunoPET Tracer Development 
Therapeutic monoclonal antibodies (mAbs) gained clinical utility in 1985 with the 
first FDA approval of the biologic, muromonab-CD3 (Orthoclone OKT3), specific for 
cluster of differentiation 3 (CD3), a co-receptor present on all T-cells(5). Since then, 
applications in cancer have been exploited with the approval of rituximab (Rituxin®) in 
1997(6) followed by trastuzumab (Herceptin®) in 1998(7).  By 2016, there were 24 
monoclonal antibodies (mAbs) and antibody drug conjugates (ADC) approved by the FDA 
for cancer treatment. These mAbs are directed to a specific target ranging from tumor 
and cell-surface associated antigens to biomarker signatures within the tumor 
microenvironment. Despite their specificity and moderate safety profile, clinical efficacy 




unpredictable tumor antigen density, ii) internalizing status of the mAb:antigen complex, 
iii) the success at which the antibody reaches the target, iv) vascular penetration, and, v) 
tissue distribution, which may impact adverse events (8–12). All of these factors 
underscore the need for precision medicine, borne out of the intent of tailoring the disease 
treatment and prevention by providing the right drug to the right patient at the appropriate 
time and dose.  
A logical approach to precision medicine explores non-invasive imaging tools that 
can be repeatedly utilized to profile tumors at the molecular level, and to augment flaws 
present in biopsies from tumor heterogeneity or poor sample quality. With this 
perspective, antibody or immune-based positron emission tomography (immunoPET) 
was developed to provide a direct readout of antigen density present within each lesion; 
moreover, the pharmacokinetic and dosimetric properties of the mAb, in the case of 
radioimmunotherapy, can be considered cognate when compared to the imaging tool(13). 
Taken together, immunoPET has a high potential to influence and direct informed 
decisions in drug design and development.  
The development of immunoPET tracers relies on the following principles: i) the 
biological and chemical properties of the mAb, ii) the radionuclide chosen iii) the chelate 
selected, and iv) the stability of the linker between mAb and chelate.  MAbs for patient 
use are either humanized or made fully human to prevent human anti-mouse antibody 
response (HAMA)(14). The size of full-length biologics (~150 kDa) prolongs their half-life 
in the blood, which affects the time it takes to deliver to the tumor target and clearance 
from healthy tissues.  Thus, pairing mAbs with long-lived radionuclides 64Cu (t1/2 ~ 12.7 





One limitation to using full mAbs specifically for imaging purposes is the long wait 
times between tracer administration and imaging acquisition, as well as higher radiation 
exposure of non-target organs. Tracer pharmacokinetics can be improved by decreasing 
its size, effectively reducing circulation time, and minimizing dose exposure to the 
patient(16). With this perspective, smaller fragment constructs are engineered offering 
shorter blood residencies and faster tumor target delivery. These fragments mostly retain 
the variable region where the antigen-binding site is primarily located. Suggested PET 
radionuclide tags to complement mAb fragments are provided in Table 2. Moderately-
sized fragments (i.e. F(ab)’2 (~100-110 kDa), minibody (~75 kDa), and diabody (~50 
kDa)) may be appropriately labeled with 18F (t1/2 ~ 109 min), 64Cu (t1/2 ~ 12.7 h) and 86Y 
(t1/2 ~ 14.7 h). Smaller-sized fragments like affibodies (~ 6 kDa), nanobodies or single 
domain antibodies (~12-15 kDa) can be radiolabeled with shorter-lived isotopes like 18F 
and 68Ga (t1/2 ~ 68 min), which consequently decreases the radiation exposure of the 
patient(17). The caveat herein lies in the overall rate of clearance and nuclide site delivery 






Table 2. Different antibody fragments and recommended PET radionuclide for 
companion diagnostic development 
1.1.2 Zirconium-89 immunoPET tracers 
Standardized production and commercial availability has made the development 
of Zr-89 radiolabeled mAbs relatively straightforward(17). As a radiometal, Zr-89 requires 
complexation to prevent random, non-specific binding to non-targeted tissue (usually the 
bone), which consequently lowers contrast. To date, only desferrioxamine (DFO), a 
known iron-sequestering siderophore with three hydroxamate groups is currently utilized 
as a chelate despite reports of metal:complex in vivo instability(30,31). DFO 
bioconjugation techniques were established either through non-specific attachment to 
terminal lysines(32,33) and cysteines(34) or through a more discriminate glycan selective 
labeling(35). A depiction of a mAb radiolabeled with 89Zr through a DFO linker can be 
found in Figure 2. 
Antibody Fragments Recommended  
PET Nuclide 
References 
Affibody (~7 kDa), 























Figure 2. 89Zr labeled monoclonal antibody. mAbs are conjugated to DFO at the 
terminal amine groups before undergoing radiolabeling with 89Zr. The figure only shows 
one DFO conjugated to the antibody for clarity, but in reality there are often more DFO 




Consequently, preclinical research flourished with many imaging probes 
developed to target different oncogenic molecular signatures. A significant number of 
these tracers were developed to target surface-bound biomarkers, such as i) members of 
the epidermal growth factor receptor family (e.g. EGFR(36), HER2(37) and HER3(38)), 
ii) prostate-specific membrane antigen (PSMA)(39), iii) prostate stem cell antigen 
(PSCA)(28), iv) CD20(40), v) CD44(41), vi) programmed death receptor (PD1)(42) and 
vii) programmed death ligand 1 (PD-L1)(43), to name a few. Imaging probes targeting 
secreted signaling proteins (e.g. VEGF, granzyme B, interferon-γ)(44–46), 
antigen/receptors bound to T cells (e.g. CD3(47), CD8(48)) and shed antigens (e.g. 
CA19.9(49), carcinoembryonic antigen or CEA(50)) were also investigated. With 
substantial preclinical data, a number of these tracers have progressed to clinical trials. 
The first study of a 89Zr-mAb probe (89Zr-cmAb U36) targeting CD44v6 in patients with 
head and neck cancer was reported in 2006(51).   The number of 89Zr-based immunoPET 
probes in the clinic tripled in 2013(30). As of this writing, to the best of our knowledge and 
after extensive search at clinicaltrials.gov, there are ~46 89Zr-mAbs that are currently 
undergoing or have completed patient trials, none of which are FDA approved. An 
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Multiple Myeloma NCT01859234 Unknown 
Breast Cancer NCT01081613 Completed 
Neuroendocrine Tumors NCT01338090 Completed 
Renal Cell Carcinoma NCT01028638 Completed 
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MSTP2109A STEAP1 Prostate cancer NCT01774071 
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Table 3. List of 89Zr-immunoPET tracers that advanced to clinical trials 
1.1.3 Clinical Impact of Companion Diagnostics 
Understanding the molecular profile of a malignancy is necessary to determine 
treatment indications. A standard clinical strategy obtains tumor specimens through 
surgical or core needle biopsies in solid tumors for histopathological analyses. One can 
also analyze blood, urine, sputum, or cerebrospinal fluid, for circulating biomarkers(52). 
Biopsy-driven molecular profiling is often fraught with problems and limitations since 
access to the tumor sites may be difficult, often requiring complicated invasive 
procedures(53). Additionally, biopsies only sample a small portion of the global tumor, 
and analysis could miss important tumor characterizations. Tumor heterogeneity renders 
biopsies inconsistent, which can inadequately portray the presence and level of 
expression of the molecular signature; thus, requiring more tests to accurately 
characterize the tumor. Consequently, proper histopathological analysis of the 
receptor/antigen density may not be reflected, potentially eliminating a patient from 
benefiting from molecular-based treatments. Repeat biopsies are performed on patients 
to pathologically confirm malignancy to direct treatment decisions, but secondary biopsy 
results may not match the original pathology report(54). Moreover, multiple sequential 
biopsies are deemed impractical, unethical, and unsafe(55). In this regard, using a PET 
KN035 PD-L1 Advanced solid tumors NCT03638804 
Not yet 
recruiting 
ABT806 EGFR VIII Glioma NCT03058198 Recruiting 
Certolizumab TNF-α Rheumatoid Arthritis NCT03546335 
Phase 1; 
Recruiting 
Avelumab PD-L1 NSCLC NCT03514719 
Phase 1; Not 
yet recruiting 
RO5429083 CD44 Neoplasms NCT01358903 
Phase 1; 
Completed 




probe to profile tumors could reduce cases of biopsy mismatch by looking at the entire 
tumor in an unperturbed, non-invasive setting.  
ImmunoPET may potentially provide an image-guided molecular diagnostic tool 
where pathological results may not be able to confirm and identify true positive disease. 
It detects the target antigen and quantitatively measures its expression. The imaging 
agent 18F-FDG has long been the standard PET tracer for detecting lesions, but it is 
limited to visualizing tumor metabolism. Moreover, weak tumor avidity or probe 
accumulation, non-specific tissue binding, and low metabolic lesions can pose problems, 
hindering detection(56). Pandit-Taskar et al. conducted identification of metastatic bony 
lesions using the anti-PSMA PET tracer, 89Zr-J591 and analyzed against lesions detected 
by 18F-FDG, bone scans (99mTc-medronic acid (MDP)) and computed tomography (CT). 
89Zr-J591 was able to detect four occult lesions, which were undetected by FDG and other 
imaging assays(57).  Out of 21 lesions, 19 were PSMA-positive as identified by 89Zr-J591. 
Of these select osseous lesions, two were biopsy-proven negative, but further 
assessment using magnetic resonance imaging confirmed one of the lesions as 
metastatic with a repeat biopsy confirming the malignancy.  
 Dose escalation studies using 89Zr-IAB2M (anti-PSMA minibody) in patients were 
conducted with 10 mg, 20 mg, or 50 mg of IAB2M (Fig. 3)(58). Differences in 
biodistribution were minor across all doses. Decreased blood pool activity coupled with 
an increased liver and GI tract accumulation was observed over time. The highest lesion 
uptake was seen in the 10-mg cohort with optimal biodistribution for imaging, as well as 




resulted in slower serum clearance due to mass effects, although a non-significant 
decrease in liver uptake was noted in the 50 mg cohort.  
Figure 3. Confirmation of malignancy Differences in lesion detection in a metastatic 
prostate cancer patient using 99mTc‐MDP (bone scan) showed lesions in the ribs and 
vertebrae (A), 18F‐FDG PET scan displayed uptake in the femur and in the vertebrae 
(B), and 89Zr-IAB2M imaging identified more true‐positive lesions than 99mTc‐MDP and 
18F‐FDG (C). A comparison of serum clearance (D) and lesion uptake (E) between 
89Zr‐IAB2M (minibody) and 89Z-J591 (full length mAb cognate) over time. This research 
was originally published at JNM Pandit-Taskar N,Donoghue JA, Ruan S, et al. First-in-Human 
Imaging with 89Zr-Df- IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate 
Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. J Nucl 






Perhaps the most impact immunoPET has contributed can be gleaned from the 
pioneering study investigating the biodistribution of 89Zr-trastuzumab in patients with 
metastatic BC (Fig. 4). Djikers et al. observed rapid hepatic excretion and low blood pool 
levels of the tracer in breast cancer (BC) patients who are naïve to trastuzumab with 
extensive HER2+ tumor mass in the liver; consequently, a false-negative readouts in 
distal metastatic sites was exhibited(59). The hepatic “sink” and poor uptake in metastatic 
lesions were attributed to slow extravasation of the drug through the vascular 
compartment compared to fast pharmacokinetic clearance of the mAb at low dose levels. 
In this study, a 10 mg and 50 mg loaded dose displayed terminal half-lives of 1.5 and 4.3 
days respectively; in contrast, tumor penetration and accumulation of 89Zr-trastuzumab 
occurred between 4-5 days. To gain perspective, administered therapeutic doses (4 
mg/kg loading plus 2 mg/kg maintenance dose) reached an average terminal half-life of 
~28.5 days when at steady state. Another important finding of this pivotal clinical trial was 
the importance of drug receptor occupancy. The fast pharmacokinetics of low 
trastuzumab doses led the authors to estimate drug/receptor occupancy by considering 
the amount of HER2 per tumor cell and the liver mass of the patient. The mass (1.2 kg) 
was obtained through image analysis of normalized PET/CT scans. The authors 
rationalized that a 50 mg dose of trastuzumab, equivalent to 2.0×1017 trastuzumab 
molecules (via conversion through Avogadro’s number) cannot fully saturate over a kg 
(1.2 kg) of tumor tissue based on the following approximations. A gram of tumor tissue is 
nearly comprised of ~1 × 109 cells. Each single cell, on average, possesses 2 million 
HER2 receptor sites. Thus, in the patient’s case, there are ~2.4 × 1018 HER2 receptor 




g tumor tissue × 1×109 cells/g × 2×106 HER2 receptors/cell)(60,61). The majority of the 
dose (50 mg) accumulated in the extensive liver metastasis. This created the impetus to 
vary doses in patients who are naïve to trastuzumab versus those receiving this treatment 
with the former requiring more mAb administered (50 mg vs. 10 mg, respectively).  
 
Figure 4. Receptor Occupancy. 89Zr‐trastuzumab PET biodistribution in patients given 10 
mg of 89Zr‐trastuzumab (untreated) (A), 50‐mg 89Zr‐trastuzumab during concurrent 
trastuzumab treatment (B), and 10‐mg 89Zr‐trastuzumab during concurrent trastuzumab 
treatment (C) show different clearance rates in the blood pool (D), and should be considered 
when dosing patients in the clinic. This research was originally published at Clin Pharmacol 
Ther. Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zr-trastuzumab 
and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin 
Pharmacol Ther. 2010;87(5):586-592.  
 
Taken together, these pivotal biodistribution studies underscore the substantial 
dependence of mAb-based therapies (e.g. ado-trastuzumab emtansine (T-DM1)(62), 
pertuzumab(63), rituximab(64)) on pharmacokinetics for personalized dosing strategies. 
Current clinical protocol relies on body weight to determine drug doses administered. 
ImmunoPET CDx can potentially transform this practice by facilitating the assessment of 
effective patient-tailored doses based on the extent of tumor burden and mAb 
pharmacokinetics.  
A clinical study assessing 89Zr-rituximab as an imaging biomarker of CD20 in 
patients with relapsed or refractory diffuse large B cell lymphoma was correlated against 




concordance with the tumor uptake of 89Zr-rituximab. A strong uniform staining of CD20 
was correlated with a high SUVpeak of 12.8 while a moderate, heterogeneous CD20 
expression corresponded to a tumor uptake of SUVpeak ~ 3.2-5.4. In certain cases, the 
pathology may lead to discordance with the immunoPET data. One patient demonstrated 
a biopsy-mismatch with CD20 PET displaying a positive tumor uptake (SUVpeak ~ 3.8) but 





















Figure 5. ImmunoPET findings in relation to pathology. Concordance (A) and (B) 
discordance of 89Zr‐rituximab‐PET/CT (left) with CD20 pathology via IHC (right). Arrows point 
to lesions on the PET scan. This research was originally published at PLOS One Jauw YW, 
Zijlstra JM, de Jong D, et al. Performance of 89Zr-Labeled-Rituximab-PET as an Imaging 
Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory 
Diffuse Large B Cell Lymphoma. PLoS One. 2017;12(1):e0169828 and modified for use 






Another concrete example was presented by Ulaner et al. investigating HER2-PET 
in patients with HER2-negative primary BC (Fig. 6) (54). Of the 20 patients, 15% (3/20) 
were identified by 89Zr-trastuzumab as having unsuspected HER2-positive metastases 
with proven pathologies. In this study, a patient who was diagnosed with ER+/HER2- 
invasive ductal BC presented two years later with several bone lesions and was observed 
HER2-PET avid. Biopsy of the right ilium (SUV~ 5.9) confirmed metastases but with an 
ambiguous IHC score of 2+. Confirmation of the foci as true-positive was made using 
MSK-IMPACT assay. Of note, the authors emphasized that the intensity of the PET tracer 
on foci can indiscriminately assess true- from false-positive lesions. The study reported 
~30% (6/20) of the patient population was conservatively categorized as false-negative 
due to negative pathology even with foci avidity for the probe. The relatively high 
incidence of false-positive lesions was attributed to non-specific uptake of free Zr-89, 
particularly in osseous sites, which marginalizes the use of this nuclide for detecting bone 
metastases.   
Collectively, tumor heterogeneity can impact go/no-go treatment decisions with 
standard biopsy results rendering ambiguity to some extent. In these cases, immunoPET 
can reinforce and potentially resolve equivocal tumor pathology. However, confirmation 
of true-positive or -negative lesions as visualized by immunoPET needs to be 






Figure 6. PET readout gave true-positive results despite discordance with biopsy 
findings. PET readout gave true‐positive results despite discordance with biopsy findings. 
An ER+/HER2‐ invasive ductal BC patient with confirmed negative pathology in the primary 
lesion (A) but presented with HER2‐PET positive disease 2 years after primary diagnosis (B). 
Biopsy of the same site resulted in an ambiguous IHC score (2+) (C) Red arrow points to the 
lesion. MSK‐IMPACT assay confirmed the foci as true‐positive (D). This research was 
originally published in JNM. Ulaner GA, Hyman DM, Ross DS, et al. Detection of HER2-
Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-
Trastuzumab PET/CT. Journal of Nuclear Medicine : official publication, Society of Nuclear 
Medicine. 2016;57(10):1523-1528. ©by the Society of Nuclear Medicine and Molecular 
Imaging, Inc. 
 
A first-in-human study investigated by Lamberts et al. evaluated 89Zr-MMOT0530A 
in pancreatic tumors and metastases expressing mesothelin (MSLN)(66). Pre-treatment 
scans showed a mean SUVmax of 11.5 ± 5.6 lesions in the pancreas. Patients received 
the antibody-drug conjugate DMOT4039A (MMOT0530A bound to MMAE) followed by 
89Zr-MMOT0530A PET, 4 days post injection of the tracer. After treatment, 9 out of 11 
patients presented with stable disease, and two patients had progressive disease. Those 
with progressive disease showed an uptake in liver metastasis with the PET tracer. This 




as well as guide individualized antibody-based treatment with the ADC DMOT4039A.  
The landmark ZEPHIR study evaluated the predictive value of HER2 PET/CT in 
combination with FDG PET prior to T-DM1 treatment in patients with metastatic breast 
cancer (Fig. 7)(67). From the 55 patients enrolled, 16 (29%) were negative for HER2-PET 
while 39 patients were categorically classified as positive for HER2-PET/CT, depending 
on lesion heterogeneity. From the HER2-positive pool, 28 patients displayed an objective 
response (OR) after 3 cycles of T-DM1. In combination with post-treatment (after 1 cycle 
of T-DM1), a 100% positive predictive value (PPV) was achieved for HER2-PET imaging 
(72% PPV) in combination with early treatment FDG-PET imaging based on RECIST 1.1.  
Moreover, a time-to-treatment failure of ~ 11.2 months in the HER2-positive group and 
~3.5 months for the HER2-negative group were identified. A negative predictive value of 
88% in patients with low HER2-PET was deemed clinically significant.  To date, this is the 
first trial that used a three-prong strategy that employed imaging biomarkers for go/no go 
treatment decisions in the clinic. In conclusion, these clinical trials highlighted the potential 
of immunoPET to measure functional effects of targeted treatment, making this imaging 












































Figure 7. Predictive markers of treatment. Time‐to‐treatment failures were evaluated 
based on HER2‐PET/CT (A), early FDGPET/CT (B) and combination of both HER2‐ and 
FDG‐PET/CT (C). This research was originally published in Ann Oncol. Gebhart G, Lamberts 
LE, Wimana Z, et al. Molecular imaging as a tool to investigate heterogeneity of advanced 
HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine 




1.1.4 Practical Considerations 
While immunoPET CDx may seem straightforward, several aspects of using this 
imaging technique need to be deliberated. The amount of dose administered and the 
interval between tracer administration and imaging acquisition warrant investigation to 
obtain an optimized contrast between lesions and background. In the case of 89Zr-
trastuzumab, the optimal imaging time for a ~37 MBq (50 mg) intravenous injection was 
observed between 4-5 days after injection(59). At this period, low blood pool activity and 
high tumor avidity was established. Imaging at longer periods >6 days can compromise 
the spatial resolution and image quality(59). At higher activities (~185 MBq/50 mg) 
administered, 89Zr-trastuzumab still generated high quality spatial resolution in images 
acquired between 5-6 days post-injection(68). The scan periods of 4-6 days depending 
on the dose are typical for other full-length mAb tracers in clinical trials(54,65,68,69). For 
smaller biologics-based tracers, 89Zr-IAB2M, for example, demonstrated shorter interval 
wait times with the best lesion to background ratio identified at 48 h p.i.(58) Safety profiles 
of 89Zr-labeled mAbs require careful assessment to limit radiation-related toxicities. Whole 
body effective doses reported in a number of early phase studies ranged from 0.41 
mSv/MBq for 89Zr-IAB2M(58), 0.87 ± 0.14 mSv/MBq for 89Zr-ibritumomab tiuxetan(70), 
0.47 mSv/MBq for 89Zr-trastuzumab(71) and 0.264 mSv/MBq for 89Zr-panitumumab(18) 
whereas FDG-PET(72) had a reported mean effective dose of 0.0199 ± 0.0032 mSv/MBq.  
 Engagement of immunoPET CDx as predictive imaging biomarkers in the clinic 
should continue to be explored in the clinical translational efforts toward precision 
medicine. It has already shown success in accurately profiling lesions at the molecular 




determining the biodistribution of therapy before treating the patient. Sequential imaging 
in test-retest studies can provide a viable tool to appropriately dose patients, but should 
be used with caution during treatment regimens.  In a nutshell, immunoPET is still at its 
early stages of clinical development and will most likely require further standardization 
(i.e. streamlined SUV readout analysis, chemistry optimization) and validation through 
other molecular profiling tools. Once harnessed, its benefits can provide a powerful 
impact in patient management.  
1.2 Overview of Breast Cancer and Selected Subtypes 
Breast cancer (BC) is the most commonly diagnosed cancer in women, as well as 
the leading cause of cancer-related deaths(73). BC is typically referred to as a single 
disease, but it is clinically and molecularly heterogeneous, with many ways to categorize 
tumors. Still, clinical decisions rely on the assessment of three markers: the expression 
of the estrogen receptor (ER), progesterone receptor (PR) and the overexpression of the 
human epidermal growth factor receptor 2 (HER2)(73). The accurate assessment of 
these biomarkers assists in tumor classification and aids in appropriate treatment 
decisions. This section will mainly discuss HER2 and EGFR, molecular therapeutic 
strategies, and current diagnostic techniques. 
1.2.1 HER family  
The HER family is a group of transmembrane receptor tyrosine kinases (RTK) with 
four members: EGFR, HER2, HER3, and HER4 (Fig. 8). They are deregulated in many 
cancer subtypes, but are most commonly recognized in BC, lung cancers, and 
glioblastoma. In breast cancer, the EGFR gene is amplified in up to 5% of cancer cases, 




comprising of an extracellular domain, a single transmembrane domain, and an 
intracellular domain with a conserved carboxyl terminal tail and catalytic kinase 
domain(74). A key function of their activity is within the dimerization portion of the 
extracellular domain(74). When a ligand binds the dimerization domain, it changes the 
conformation of the receptor allowing for dimerization and inter-receptor interactions, 
although HER2 is the exception, since it has no known ligand(74). Table 4 describes the 
HER receptor binding combinations. 
After dimerization, the receptors will phosphorylate their tails and activate 
downstream signaling cascades, such as the phosphatidylinositol-3-kinase (PI3K)/Akt 
pathway, the Janus kinase, and phospholipase C pathway; all which affect and promote 
cell proliferation, survival, and adhesion(75). Additionally, the Src pathway responds to 
upstream HER family signaling(75). The signaling potency of receptors is governed by 
the particular dimer pair. For example, heterodimers are more active than homodimers, 
with the heterodimer HER2-HER3 possessing the most signaling activity(76). 
Figure 8. HER family members and ligands. EGFR, HER2, HER3, and HER4 are all 
capable of dimerizing upon ligand binding and activation, except for HER2 which does not have 






EGFR-EGFR EGF, EPG, TGFα, AR, BTC, HB-EGF, EPR 
EGFR-HER2 EGF, EPG, TGFα, AR, BTC, HB-EGF, EPR 
EGFR-HER3 EGF, EPG, TGFα, AR, BTC, HB-EGF, EPR, Nrg-1, Nrg-2 
EGFR-HER4 
EGF, EPG, TGFα, AR, BTC, HB-EGF, EPR, Nrg-1, Nrg-2, Nrg-
3, Nrg-4 
HER2-HER2 None 
HER2-HER3 Nrg-1, Nrg-2 
HER3-HER3 Nrg-1, Nrg-2 
HER3–HER4 BTC, HB-EGF, EPR, Nrg-1, Nrg-2, Nrg-3, Nrg-4 
HER4-HER4 BTC, HB-EGF, EPR, Nrg-1, Nrg-2, Nrg-3, Nrg-4 
Table 4. HER family member dimer pairs and activating ligands. 
1.2.2 EGFR 
The human epidermal growth factor receptor 1 (EGFR) or HER1 is a 
transmembrane protein comprised of an extracellular ligand binding domain, a 
transmembrane domain, and a cytoplasmic domain with kinase activity (Figure 9). When 
its ligands, such as EGF, transforming growth factor α (TGFα), or amphiregulin (AR) binds 
to the extracellular region, a conformational change on the EGF receptor is triggered that 
allows dimerization with another EGFR molecule, or a heterodimer with another RTK(77). 
Upon dimerization, EGFR kinase is activated, allowing for autophosphorylation and 
transphosphorylation of the intercellular tails that serve as docking sites for downstream 
proteins containing the Src Homology 2 (SH2) domain(77). The primary activated 




activation of Src tyrosine kinases have been documented(77). Additionally, EGFR can 
signal from different compartments of the cell including the nucleus. 
 The nuclear EGFR (nEGFR) signaling network has recently been implicated in 
cancer progression and response to EGFR-targeted therapies. nEGFR has been 
detected in cancer cells of primary tumor specimens, as well as other highly proliferating 
tissues(78–81). Additionally, high expression of nEGFR has been correlated with poor 
clinical outcome in patients with breast cancer, in particular(82), as well as in many other 
cancers(82,83).  Due to the many pathways that EGFR functions within, EGFR as a 
treatment target has been strongly pursued over the last 30 years(77). 
1.2.3 EGFR expression in TNBC 
Approximately 10-20% of global BC patients will be diagnosed with a tumor lacking the 
three targetable biomarkers, ER, HER2, and PR, and are considered “triple negative” 
(84). TNBC is a more aggressive BC subtype, disproportionately affecting premenopausal 
African or Hispanic women, and accounts for 25% of BC deaths(85). TNBC patients have 
a poorer outcome compared to other BC subtypes presenting with known molecular 
targets, and many of these tumors must be treated with chemotherapy as the mainstay 
in the neoadjuvant, adjuvant, and metastatic setting(85). Yet despite promising results, 
there have been cases of increased toxicity without improvements to survival(86). This 
may be in part due to the fact that BC is a heterogeneous disease with complex variances 
in genes, epigenetics, and protein expression within each individual’s tumor(87). Due to 
this complexity, efforts have been made to classify tumors into subgroups based on 




















Figure 9. EGFR trafficking to the nucleus. Upon ligand binding and activation, EGFR 
homodimerizes and induces transautophosphoylation. This causes internalization to 
endocytic vesicles. EGFR then undergoes translocation through the Golgi apparatus and 
into the endoplasmic reticulum outside of the nucleus. EGFR then moves through the 
outer and inner nuclear membranes through the nuclear pore complex. Finally, EGFR 
interacts with Sec61 and is released from the ER into the nucleus. 
 
Lehmann and colleagues have defined six new TNBC subtypes based on gene 
expression profiles: basal-like 1, basal-like 2, mesenchymal, mesenchymal stem-like, 
immunomodulatory, and luminal androgen receptor(89). Within these subtypes, there is 




pathways, such as PARP inhibitors, anti-angiogenic antibodies and inhibitors, PI3K and 
mTOR inhibitors, AKT inhibitors, and immunotherapy, to name a few(90). One of these 
actionable pathways has been shown to be EGFR. In one study, EGFR was 
overexpressed in 89.47% of cases of invasive BC(91). Similar results were also observed 
in a study among 151 TNBCs where 27% of cases were scored as 3+ for EGFR and 37% 
were scored as 2+ by IHC, confirming high EGFR expression(92). Therefore, targeting 
EGFR in TNBC is a critical need. 
1.2.4 EGFR targeted therapies in BC  
To date, two successful approaches towards targeting EGFR in cancer therapies 
have been explored. The first approach involves targeting the kinase activity of the 
receptor through the use of tyrosine kinase inhibitors (TKIs) that bind to the ATP-binding 
sites of the receptor. There are currently three FDA approved TKIs – erlotinib (Tarceva®), 
gefitinib (Iressa®), and lapatinib(Tykerb®)(93). A second approach uses mAbs to target 
the extracellular domain of EGFR and block natural ligand signaling and dimerization, 
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Cetuximab was FDA approved in 2006 for the treatment of colorectal cancers in 
the metastatic setting(94). It is a chimeric monoclonal antibody that targets domain II of 
EGFR with a higher binding affinity than natural ligands transforming growth factor (TGF) 
and EGF, effectively blocking the ligand-binding domain and preventing dimerization(77). 
Similarly to trastuzumab, cetuximab is capable of antibody-dependent cell-mediated 
cytotoxicity (ADCC) and complement-dependent cytotoxicity(95,96).  Cetuximab can also 
block EGFR phosphorylation and promotes internalization of the receptor which reduces 
proliferation(97). Upon cetuximab binding to EGFR, phosphorylation will be induced 
which can trigger downstream responses such as aberrant growth signals or 
apoptosis(98,99). Due to its efficacy, it has been combined with many other treatments 
such as chemotherapy and radiotherapy, resulting in tumor depletion in mice, and 
improved chemotherapy efficacy in humans(100). It has limited dose toxicities, with only 
about 10% of patients reporting a severe toxicity(101). 
Surprisingly, clinical trials focusing on EGFR-TKIs and mAbs in TNBC have been 
disappointing, potentially due to resistance mechanisms(77). These pathways of 
resistance include the angiogenesis pathway, increased EGFR degradation, 
dysregulation of EGFR internalization, oncogenic shift (increased expression of other 
HER family members), constitutive activation, and increased expression of ligand growth 
factors(77).  
 Cetuximab as a monotherapy has shown dismal response rates in TNBC(102). In 
a phase II clinical trial, patients who received one or fewer chemotherapy regimens were 
randomly assigned to cisplatin plus cetuximab, or cisplatin alone. While cetuximab alone 




objective response rate, suggesting there is hope for cetuximab in TNBC(102).  
In another phase II clinical trial on metastatic TNBC patients, Carey et al. had 
patients receive cetuximab alone or with carboplatin after progression. Overall response 
rates were 6% with cetuximab alone, or 17% with combination therapy, and EGFR 
expression as a single marker did not provide a significant correlation with clinical 
response(103). Due to its failure to yield improved response rates using EGFR-targeting 
mAbs without prior EGFR profiling, it has been suggested to stratify patients first by their 
expression of target biomarkers before they undergo treatment, and has been explored 
in colorectal cancer with some success. 
Due to its success in other cancers, investigations have been made to find 
biomarkers to better stratify patients and predict responses. Most obvious, EGFR 
expression levels were hypothesized to correlate with cetuximab response. 
Unfortunately, early clinical trials failed to find a correlation between EGFR expression 
and clinical response to EGFR therapy in BC(104). This finding led to the belief that IHC-
based EGFR measurements are not robust predictors for cetuximab therapy, and they 
moved onto other methods, such as EGFR copy number and mutation status. So far, only 
KRAS mutations(105), BRAF mutations(106), and IGF1R expression(107) status have 
correlated with response to cetuximab therapy, which none of these biomarkers have 
been implemented in TNBC, highlighting a need for an approved method to monitor 
EGFR-therapy response rates. One notable resistance pathway to cetuximab treatment 
in TNBC was highlighted as the subcellular localization of EGFR (108). 
1.2.5 HER2-positive BC 




BCs(109). Albeit significant efforts to develop anti-HER2 agents, there is still a significant 
number of patients with HER2+ BC that progress within 5-10 years of treatment(109). 
The value of HER2 as a prognostic factor is controversial. In 88% of early studies looking 
at over 40,000 cancer patients, harboring the HER2 amplified gene or HER2 protein 
overexpression was a negative prognostic factor for traditional chemotherapy, 
independent of other prognostic variables(109). However, the advent of HER2 specific 
treatments, such as the monoclonal antibody trastuzumab (Herceptin®), has improved 
treatment outcomes for patients in the adjuvant and metastatic setting(102). Trastuzumab 
has been tested in many major clinical trials for patients with HER2+ breast cancer, with 
the median overall response rates ranging from 15.6-25.1 months(109). 
1.2.6 Current companion diagnostics for HER2-positive BC 
Due to the prognostic value of HER2-receptor presence and response to HER2-
targeted treatment, it is now recommended that all primary, metastatic, and recurrent BC 
be tested for HER2(110,111). Currently, there are many FDA-approved in vitro 
companion diagnostics for HER2 overexpression, including five immunohistochemistry 
assays (IHC), three tests to quantify HER2 gene copy numbers through fluorescence in 
situ hybridization (FISH), one chromogenic in situ hybridization (CISH), and a dual in situ 
hybridization (ISH) assay(109). These in vitro diagnostic techniques require an invasive 
procedure of collecting sample tissue from a patient. Due to tumor heterogeneity, the 
sample collected may not fully represent the entire tumor microenvironment, potentially 
yielding inconclusive results. Additionally, tissue can only be collected from a patient with 




IHC staining is a semi-quantitative, but subjective, method for determining HER2 
status, since HER2 is expressed in all breast epithelial cells. Results are scored from 0 
to 3+, which measures the amount of HER2 protein present in the cell, with a score of 3+ 
called “HER2 positive”(112). Although IHC is an available, low cost, and easy method to 
determine HER2 status, its interpretation is subject to reader bias(112). For example, 
comparing HER2 overexpression measured by IHC on-site and HER2 amplification 
measured by FISH at a reference lab revealed low concordance rates (66-87%)(112). 
FISH, on the other hand, is more reliable and sensitive, but it requires special equipment 
and training to appropriately perform the test(113). Additionally, HER2 expression can 
vary between primary and metastatic sites, making it difficult to characterize each 
individual lesion(114,115).  
On the other hand, fluorescence in situ hybridization (FISH) testing is an 
automated slide-based DNA-hybridization using fluorescent probes. It is a more objective 
scoring system, although it is an expensive test and requires specialized microscopes. 
Chromogenic in situ hybridization (CISH) is a similar test where instead of a fluorescent 
probe, a chromogenic probe is used. These tests are binary, providing a “positive” or 
“negative” HER2 score, and not a numeric value.  
Since the advent of immunoPET, efforts have been made to use imaging as a 
means to characterize breast lesions with trastuzumab as a tracer. In a study by 
Dehdashti et al., women with HER2+ and HER2- BC underwent a PET/CT scan after 
administration of a 89Zr-labeled HER2-specific antibody (trastuzumab)(116). The PET/CT 
uptake was correlated to HER2 status determined by IHC or FISH of a primary or 




and 93.7% of HER2- patients had a negative PET/CT scan. This translated to a positive-
predictive value of 83.3% and a negative predictive value of 50% in differentiating HER2 
positive from negative tumors. They conclude that 89Zr-trastuzumab has the potential to 
characterize the complete tumor burden in BC patients for HER2 status, obviating the 
need for multiple invasive tissue samples. Additionally, it addresses the issue of 
interpatient heterogeneity of HER2, and can further aide in treatment decisions. 
1.2.7 HER2-targeted treatment strategies  
At time of writing, there are five FDA-approved targeted therapies for HER2+ 
disease, including monoclonal antibodies (mAb), antibody-drug conjugates (ADC), and 
small molecule inhibitors (Table 6).  
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Table 6. FDA approved HER2-targeted treatments for HER2+ BC 
Trastuzumab (Herceptin®) is a humanized monoclonal antibody targeted against 
HER2. It was approved in 1998 for the treatment of metastatic HER2+ disease, and was 
the first anti-HER2 agent on the market. In 1998, the “pivot trial”, a randomized phase III 
trial testing chemotherapy alone versus chemotherapy and trastuzumab, showed a 
median overall survival of 25.1 months in patients who received trastuzumab, and 




year(109).  It has radically improved outcomes in HER2+ breast cancer patients, with a 
study in 2014 of 4,000 patients showed that adding trastuzumab to chemotherapy 
improved overall survival from 75.2% to 84%, and is listed as an essential medicine by 
the world health organization(122,123). Its mechanism of action is not fully understood, 
but it is thought to evoke antibody-dependent cellular cytotoxicity (ADCC), disrupt 
downstream signaling pathways, inhibit cell cycle progression, and act as an 
antiangiogenic agent upon binding to HER2(124). Early clinical response rates ranged 
from 12-68% response, with the best responders observed in patients with an IHC or 
FISH score of 3+. The addition of trastuzumab to other therapies increased progression 
free survival by 2-3 months(124). The success from these trials and the many others has 
resulted in a 1 year-long cycle of adjuvant trastuzumab as standard of care for HER2+ 
tumors, as well as provided proof-of-concept that targeting HER2 would improve patient 
outcomes. 
The phase III study comparing lapatinib (Tykerb®), an oral TKI of HER2 and 
EGFR, to capecitabine in patients with HER2+ metastatic breast cancer improved 
progression free survival(125), and, therefore led to its FDA approval in 2007. Recently, 
two antibody-based therapies and a small molecule TKI were FDA approved: 
pertuzumab, TDM-1 and neratinib. Pertuzumab (Perjeta®) prevents the pairing of HER2 
and HER3; the results from the phase III CLEOPATRA study demonstrated a synergistic 
effect achieved when pertuzumab was combined with trastuzumab and docetaxel with 
patients showing improved progression free survival(126). TDM-1 (Kadcyla®), approved 
in 2013, links a cytotoxic agent to trastuzumab, specifically delivering emtansine to 




progression free survival of TDM-1 compared to capecitabine plus lapatinib(127). Finally, 
neratinib (Nerlynx®) is an oral TKI that inhibits EGFR, HER2, and HER4, approved in 
HER2+ patients based on the exteNET phase III clinical trial(128). A phase III trial of 
women with stage 1-3 HER2+ BC who previously completed trastuzumab therapy, 
patients were randomized to neratinib (Nerlynx®) or placebo. Those who received 
neratinib had significantly improved 2-year disease free survival. 
More new HER2 agents or potential combination therapies either under preclinical 
development or FDA-approved for other HER2+ cancers can be potential treatments in 
BC in the future(129). HER2 antibodies MGAH22, MCLA-123, and ZW-25, and ADCs 
SYD 985 and DS-8201 are all past phase I clinical trials. New TKIs tucatinib, poziotinib, 
and pyrotinib (Nerlyxn®), are all through phase II trials.  
Even with the diverse availability of treatments, because of HER2 mutations 
(intrinsic and acquired) causing drug resistance, there are differences in sensitivity 
between patients and therapies. Changes in downstream pathways or activation of 
parallel oncogenic pathways can potentially contribute to resistance. Particular attention 
should be given to identifying acquired resistance mechanisms to help optimize HER2 
directed therapies(130). 
1.3 Mechanisms of resistance to treatment in BC 
In hormone receptor positive BC (ER+ and PR+), endocrine therapy is the 
mainstay(131). Endocrine therapy includes the use of selective ER modulators (SERMS) 
which act as tissue specific estrogen receptor agonists and antagonists. Selective ER 
down regulators (SERDs) competitively bind ER with a greater affinity than SERMs, and 




synthesis and prevent their growth-stimulating effects. Development of resistance is 
thought to be due to genetic factors (ESR1, CCDC170 mutations, for example), loss of 
ER expression, crosstalk between compensatory receptors (HER2, EGFR)  and 
epigenetic factors(132). For TNBC, first line neoadjuvant platinum-based or taxane 
chemotherapy is the mainstay, and comes with its own set of challenges. Most often, 
resistance stems from an increase in the cell’s ability to efflux the drug, which results in 
decrease net intracellular accumulation(133). In HER2+ BCs, resistance pathways can 
develop after trastuzumab (Herceptin®) therapy from upregulation and compensation 
from other HER family members, epitope masking, and enzymatic cleavage of the 
trastuzumab binding site(134). Additionally, cells can develop adaptive responses by 
down-regulating tumor suppressors PTEN and PI3K/Akt(135,136), or through alteration 
of downstream pathway signaling, through the PTEN/PI3K/AKT/mTOR pathway, and 
even the Src pathway(137).  
1.3.1 Overview of Src 
Src is expressed in all normal, mammalian cells and is classified as a proto-
oncogene(138). The Src gene produces a protein produced called Src that is a member 
of the Src family kinase (SFK) group, which is a group of non-receptor tyrosine 
kinases(138). SFKs are involved in many cellular processes and their aberrant signaling 
has been associated with tumor promoting events, such as cell proliferation and 
survival(138). The most studied mechanism of Src function is its interaction with RTKs, 
such as EGFR and HER2 through its SH2 and SH3 domains(139). Src also plays a role 




adhesions, and invasion (Fig. 10)(140).  
Pre-clinically, Src appeared as a promising therapeutic for cancer, although 
efficacy of single agent Src inhibitors in solid tumors has not shown promise in Phase II 
clinical trials(139). This is in part due to its activation in many resistance pathways. In 
particular, SFKs are an important component in chronic myelogenous leukemia (CML) 
due to their direct interaction with BCR-ABL(141). Src is shown to be involved in steroid 
receptor signaling and endocrine resistance(142). Src activation is observed in 40% of 
ER-positive (143) and in up to 70% of primary human BC with concomitant HER2 or 
EGFR expression(144). The synergism between EGFR, ER, and Src facilitates hormone 
signaling and confers resistance to targeted therapies(145).  The mechanism of 
resistance most important to this body of work is the interaction between Src and the 
RTKs EGFR and HER2. It has been previously reported that in many cancers, targeting 






Figure 10. Src signaling and downstream pathways. Src interacts with many RTKs 
and facilitates their downstream signaling to promote cell survival. Major Src downstream 
activation includes: (i) AKT activation and cell proliferation, (ii) stat3 activation and 
transcription upregulation, (iii) disruption of cell-cell junctions through p120-catenin, and 
(iv) stabilization of adhesion through FAK phosphorylation. This figure was reprinted with 
permission from Trends in Pharmacological Sciences. Targeting Src family kinases in 






1.3.2 Src inhibitors  
Due to its role in promoting tumorigenesis, there has been extensive developments 
of small molecule inhibitors targeting Src dysregulation(138). Dasatinib (Sprycel™, 
Bristol-Meyers Squibb) was the first FDA-approved Src/ABL inhibitor for the treatment of 
CML(147). Other inhibitors include saracatinib (AZD0530, AstraZeneca) and bosutinib 
(SKI-606, Wyeth)(148). Src inhibitors typically have low toxicity, but as a monotherapy 
they have dismal response rates in solid tumors(139). Dasatinib in particular has shown 
< 25% clinical benefit in phase II trials in BC, prostate cancer, and melanoma(149). 
Additionally, targeting Src though dasatinib failed to show a significant clinical benefit in 
metastatic colorectal(147) and small cell lung cancer(150). Saracatinib additionally failed 
to show benefit in prostate(151), pancreatic, and metastatic head and neck cancer(95), 
gastric adenocarcinoma(152), and ER/PR negative metastatic BC(153). Not surprisingly, 
no Src inhibitors have been FDA-approved for treating solid tumors as a 
monotherapy(139). 
For the past 30 years, Src monotherapy has lacked efficacy, but recently, new 
studies have provided a foundation for future clinical trials(139). One of the challenges in 
developing Src inhibitors is the lack of biomarkers available for Src-targeted therapy, 
making patient selection and stratification difficult. Previous clinical trials were performed 
on patients unselected for Src activation. This led to poor treatment outcomes, warranting 
re-examination of the Src activation pathway in the hopes of a target for subsequent 
clinical trials. In a recent study of 23 colorectal cancer cell lines, Src pathways activation 
was observed and correlated with enhanced sensitivity to Src inhibitor saracatinib, 




improved treatment outcomes(154). In a trial of pancreatic cancer patients, Src activation 
was observed and noted. They found that patients with Src activation were more sensitive 
to dasatinib, as compared to their non-activated counterparts, and furthermore, those 
patients with Src localized to the cytoplasm had increased survival(155). These results 
highlight Src activation as a molecular target and are looked into more thoroughly in the 
next sections. 
1.3.3 Src hyperactivation and its role in trastuzumab-resistance in HER2+ BC 
Despite its success in HER2+ BC, some patients who receive trastuzumab will 
relapse. Some proposed mechanisms of resistance have included HER2 forming 
heterodimers with other family members and effectively blocking trastuzumab binding, an 
increase in expression of HER2, and shedding of the extracellular domain leaving the 
form of the receptor (p95) which does not bind to trastuzumab but retains kinase 
activity(156).  
HER2 directly associates with Src as it activates its downstream signaling and 
stability(157). It has been shown that Src signaling is up-regulated in trastuzumab 
resistant tumors(157), as well as de novo trastuzumab-resistant cells(158). A particular 
oncogenic variant, HER2Delta16, induces Src function and activates Src to confer 
trastuzumab resistance(159). Src inhibition has been shown to sensitize trastuzumab-
resistant BC to trastuzumab(158). One study has shown that combination treatment with 
saracatinib and an anti-HER2 antibody (clone H2-18) produces a greater antitumor effect 
on trastuzumab-resistant (PTEN wt) breast cancer(160). An additional study has shown 
that cells overexpressing wild-type Src were resistant to trastuzumab(158). Clinically, 




total Src abundance (p = 0.025), and patients with higher levels of phospho-Src in tumors 
had a lower clinical response rate and progressive disease after trastuzumab(158).  
1.3.4 Src and its role in EGFR-overexpressing cancers 
Src activation has been shown to promote resistance in anti-EGFR therapies. 
Particularly, Src is responsible for the full activation of EGFR(161), and it physically 
associates with activated EGFR(162). Once Src binds to EGFR, EGFR undergoes a 
conformational change. This leads to autophosphorylation at the tyrosine residue 416 
(Y416) and subsequent transient activity, which leads to phosphorylation of downstream 
targets, such as EGFR on tyrosine 845 (Y845)(144). Y845 is situated in a conserved 
position within the activation loop of EGFR, and is necessary for full activity of the 
receptor(163). It has been discovered that Src can directly phosphorylate EGFR on Y845, 
strengthening the communication between the two proteins(164). This residue also acts 
in concert with the redistribution of EGFR from the membrane to intracellular vesicles, 
and has been suggested as a marker of drug response in NSCLC, breast, and colorectal 
cancers(164). 
EGFR and Src are shown to be upregulated in a majority of lung, colorectal, and 
pancreatic cancers(165).  Additionally, Src is commonly activated in EGFR-
overexpressing cells and its activation enhances EGFR signaling of downstream PI3K-
Akt pathway(158). In one study, it was reported that cells with acquired cetuximab 
resistance have increased Src activity, potentially due to its cooperation with EGFR and 
resultant signaling to HER3 and PI3K/Akt. A decrease in HER3 phosphorylation and 
PI3K/Akt signaling is observed when cetuximab-resistant cells are treated with dasatinib, 




of breast cancers expressing EGFR, HER2, and HER3, dasatinib treatment resulted in 
apoptosis and growth inhibition in a dose dependent manner(167). This was 
accompanied by decreased EGFR and Src phosphorylation, suggesting that these two 
RTKs are prime targets for BC therapy. In non-small cell lung cancer (NSCLC) in 
particular, Src is highly active and associated with cetuximab resistance(166). Most 
notably, it has been shown in a non-small cell lung cancer cell line H226, that cetuximab-
resistance leads to overexpression of EGF, and concomitant nuclear translocation of 
EGFR mediated by Src. Treatment of these resistant cells with dasatinib resulted in loss 
of nuclear EGFR, increased membrane EGFR expression and cetuximab re-
sensitization, further supporting the hypothesis that EGFR nuclear compartmentalization 
impacts cetuximab efficacy(168). Additionally in colorectal cancer, dasatinib re-sensitized 
cetuximab-resistant tumors to cetuximab(169).  
EGFR localization, in particular, has been investigated as a potential resistance 
mechanism in breast cancer. Extensive reports have shown EGFR family members being 
shuttled from the plasma membrane to the nucleus, with nEGFR expression 
demonstrating poor clinical outcomes in breast cancer(80,81,137,170). nEGFR acts as a 
transcription factor, interacting with STAT3 and E2F1. When in the nucleus, EGFR is 
associated with gene transcription, DNA repair, and radioresistance. 
1.4 Immune oncology 
Despite significant advances in BC chemo- and molecular therapies, a proportion 
of patients with localized disease still remain refractory to treatment, or suffer relapse. 
Furthermore, those with metastatic disease are rarely cured. In BC, it is believed that 




progression(171). Particularly in TNBC, BC gene profiling has demonstrated patterns of 
immune gene activation(172). In approximately 50% of HER2+ BCs inflammatory 
signatures are observed which correlate with improved outcomes(173). Additionally, high 
levels of tumor infiltrating lymphocytes (TILs) have been associated with improved 
response to neoadjuvant chemotherapy(174). Due to these observations, recent 
advances in immunotherapy highlight the potential to harness the immune system for 
improved tumor responses in the adjuvant and monotherapeutic space (175). 
The immune system can impact tumor growth and prevention through the 
immunoediting process. This is comprised of three stages called elimination, equilibrium, 
and escape. In the elimination phase, the tumor is destroyed by inflammation, infiltration 
of effector cells, and production of tumor-inhibiting cytokines(176). The escape phase is 
characterized by sustained inflammation comprised of immunosuppressive cells and 
soluble molecules(177). In equilibrium, the tumor is neither proliferating nor dying off, and 
can turn into the other two stages based on the immune response. 
1.4.1 The immune pathway 
The primary cells responsible for killing breast tumor cells are CD8+ CTLs and 
natural killer (NK) cells. Induced CTLs target specific antigens expressed on BC cells, 
and their infiltration into the tumor microenvironment has been associated with improved 
outcomes, particularly in the TNBC or basal subtype(178). Combining immunotherapy 
and chemotherapy has also been shown to enhance the activity of CTLs and is coupled 
with enhanced antitumor effects(179), and the positive effect of vaccines has been shown 
to be achieved through CTL-mediated recognition and destruction of breast cancer(180). 




unrestricted by major histocompatibility complex (MHC) class(69). Decreased NK activity 
has been observed in patients with familial breast cancer, stage IV breast cancer, and 
during breast cancer progression. When profiling gene expression in breast cancer-
associated stroma, it has been found that CTL and NK associated genes were enriched 
and predictive of better outcomes. Overall, it has been suggested that CD8+ T cells and 
NK have strong antitumor activity against BC(181).  
It is now accepted that BCs have an infiltration of leukocytes, and this can either 
promote tumorigenesis or elimination(182) (Fig. 11), and in BC these TILs have been 
established as a putative biomarker of treatment prognosis(183). There have been many 
retrospective studies published that suggest an association between pathologic complete 
response to neoadjuvant treatment and the presence of TILs in solid tumors, potentially 
representing a robust and reproducible predictive factor(184).  Particularly, a decrease in 
regulatory T cells confers response to treatment, and restores anticancer responses in 
non-responders(184). This hypothesis has been supported by studies reporting that  
some patients treated with high-dose interleukin-2 (IL-2) show durable responses and an 
increase in response to TIL therapy, where others do not(185). More recently, the 
inhibition of PD-1 alone results in response rates of 20-30% of patients, but upon 
combination with CTLA-4 blockade, this response rate increases to 57%(186). The 
varying response rates between patients has been hypothesized to be due to TILs 
presence, with higher PD-1 responding patients having more CD8+ T cells in their tumor 
bed(187). Therefore, ways to monitor presence of TILs before selecting a treatment type 


















Figure 11. TIL infiltration and its mechanism for eliminating tumors. Tumors in the 
elimination phase (left) have an influx of active dendritic cells, NK cells, and T cells which 
produce cytokines and signals to stop tumor proliferation. In the escape phase, these 
infiltrates are now engaged with the tumor environment, and the tumor is able to 




1.4.2 FDA-approved and emerging immunotherapies 
Cancer immunotherapy is defined as the utilization of naturally derived or 
synthetically generated compounds to enhance or stimulate the immune system. The 
main types of immunotherapy include adoptive T-cell transfer, viruses, monoclonal 
antibodies, and cancer vaccines(175). During adoptive T-cell transfer, a patient’s own T-
cells are genetically engineered to recognize cancer cells. Oncolytic viruses are 
specifically modified viruses that avoid normal tissue and recognize a tumor associated 
antigen. Once inside the cancer cell, the virus will replicate and then rupture the tumor 
cell. As of writing, talimogene laherparepvec (T-VEC) is the only approved treatment of 




proteins that specifically recognize an antigen on a target cell. These antibodies will 
suppress the activity of a cancer-associated protein, or kill the cancer cell entirely(189). 
Finally, vaccines will expose the immune system to a specific antigen for prevention 
(prophylactic) or treatment(190). Once the immune system recognizes the vaccinated 
antigen on the cancer cell, they will facilitate its elimination. In this work, monoclonal 
antibodies and vaccines with respect to BC treatment will be discussed in further depth. 
 Targeted monoclonal antibodies are a mainstay in BC immunotherapy since the 
late 1990s with the advent of trastuzumab for HER2+ BC; there are a total of 32 FDA 
approved antibodies as of 2017(191). The goal of monoclonal antibodies is to target 
tumors and (a) directly kill the tumor, (b) switch the immune system to attack the tumor, 
(c), attract immune cells to the tumor microenvironment, (d) decrease tumor 
vascularization, and (e) inhibit migration(191). Currently, antibodies used in treatment are 
either used alone or in combination with cytotoxic chemotherapy, radiotherapy, inhibitor 
molecules, other antibodies, or vaccines.  
The most common use of mAbs is in the context of immune checkpoint inhibitor 
blockade, targeting CTLA-4, PD-1, or PD-L1(192). When the antibody binds to each of 
these molecules, it inhibits receptor binding; thus, blocking the immune checkpoint 
pathways from getting activated. In the case of CTLA-4 blockade, it prevents activation 
of T cells, whereas the PD-1 and PD-L1 blockade affects tumor and T-cell interactions. 
The FDA-approved immune checkpoint inhibitors are: ipilimumab (Yervoy®, anti-CTLA-
4), pembrolizumab (Keytruda®, anti-PD-1), nivolumab (Opdivo®, anti-PD-1), 
atezolizumab (Tecentriq®, anti-PD-1), avelumab (Bavencio®, anti-PD-L1), durvalumab 




including melanoma, NSCLC, and metastatic RCC(192). In 2017, the FDA approved 
pembrolizumab (Keytruda®) for adult and pediatric patients with unresectable or 
metastatic, microsatellite instability high or mismatch repair deficient solid tumors that 
have progressed following prior treatment, making it the first FDA-approved tissue 
agnostic drug, meaning that the drug is prescribed based on the presence of target 
biomarker, and not due to tumor type(193). Due to the success achieved in other tumors 
targeting checkpoint inhibitors with monoclonal antibodies, it is being tested in breast 
cancer as well through many clinical trials (Table 7). 
Table 7. List of checkpoint inhibitor antibodies currently in clinical trials and their 
BC subtype. 
Historically, vaccines have been developed for disease prevention, and have 
focused on targeting B cell immunity and producing a lasting innate immune 
response(175). Cancer vaccines, in contrast, have been developed to stimulate T cell 








































responses for the treatment of a pre-existing cancer. These vaccines target antigens 
specifically expressed or altered in the tumor, either due to mutations, splice variations, 
or overexpression(175). Early cancer vaccines targeted CD8+ T cells with short peptides 
that bound to MHC class I molecules (EMENS), but these responses were short-lived and 
ineffective. This inspired a new wave of delivery methods which would target both CD8+ 
effector T cells and CD4+ helper T cells(194). These antigens are delivered as peptides, 
proteins, named DNA, vectors, or dendritic cells(175). To enhance the response, antigen 
delivery is typically combined with adjuvants such as granulocyte-macrophage colony-
stimulating factor (GM-CSF) or water in oil emulsions(175). A list of current cancer 
vaccines can be found in table 8. 
Table 8. Current cancer vaccine clinical trials. 
 
The most advanced vaccines have targeted BC patients overexpressing HER2. 
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Cellular HER-2 peptide/adoptive HER2-specific T cells 
Allogeneic whole-cell vaccine 
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These patients have been shown to have low levels of antibodies and T cell immunity for 
HER2, and these vaccines were therefore designed to amplify this low-level 
response(191). The NeuVax (nelipepimut-S) with adjuvant GM-CSF has demonstrated 
an improved 5-year disease-free survival of 89.7% compared to control (80.2%)(195). 
There is currently a phase III study looking into the prevention of recurrence 
(NCT01479244) and a phase II study evaluating efficacy in combination with trastuzumab 
(NCT01570036). A list of ongoing vaccine clinical trials in BC can be found in table 9. 
Table 9. Current BC vaccine clinical trials. 
 
Since vaccines created by short peptides can be costly, a variety of viral vectors 
have been developed to deliver antigens. Common vectors include the poxvirus family, 
measles, and adenovirus(175). Viral vectors generate more robust immunity than naked 
DNA or peptide delivery, but after repeated load delivery they can induce antibodies 
against the viral antigens that limit immunogenicity(175). To circumvent this, viral 
vaccines use a series of vectors for immune priming. For example, the PROSTVAC 
vaccine is a recombinant viral vaccine that contains genes encoding PSA and three co-
stimulatory molecules for T cells(196). Its cousin, the PANVAC vaccine, is a recombinant 
poxviral vaccine encoding the MUC1 and CEA genes, with one T cell co-stimulatory 
Clinical Trial Identifier BC Subtype Vaccine Type 
I - NCT02427581  
(Suspended) 
TNBC Poly ICLC 
I - NCT01730118 HER2+ HER2 dendritic cell vaccine 
I/II - NCT02018458 
TNBC 
ER+/HER2- 
Dendritic Cell Vaccine 
II - NCT01570036 HER2+ E75 
I/II - NCT02061332 BC, DCIS HER2 pulsed dendritic cell vaccine 
I - NCT01376505 BC HER2 vaccine 







Dendritic cells have also been used as vaccines, since they can be generated from 
the peripheral blood of patients and are loaded with antigen peptides. These vaccines are 
typically potent, but they are technically challenging and require expertise and specialized 
laboratories for processing(175).  
 Cellular vaccines are derived from patient whole tumor cells or dendritic cells fused 
with tumor cells and injected back into the patient. Monitoring these immunotherapies, 
though, can be complex, especially since determining which of the tumor antigens are 
immunogenic, and production of this treatment is labor-intensive. The first FDA approved 
cellular vaccine was sipuleucel-T (ProvengeTM) and approved in 2010 for the treatment 
of advanced prostate cancer(197). It works by re-infusing patients with their own APCs 
that have been pulsed with prostatic acid phosphatase and GM-CSF. In the phase III 
IMPACT trial, it demonstrated improved median overall survival by 4.1 months prostate 
cancer(196). An investigational agent named lapuleucel-T (APC8024, Neuvenge) is the 
HER2 cognate of sipuleucel-T and contains peripheral blood mononuclear cells cultured 
with recombinant HER2 linked to GM-CSF, and has been studied in BC. In a phase I 
clinical trial with 18 patients, it was well tolerated, with 5.5% patients achieving a partial 
response, and 16.6% of patients achieving stable disease for up to 1 year(198). 
1.4.3 Evading immunotherapy in BC 
Regulating T cell response is necessary to minimize autoimmunity, and therefore 
the immune system has developed a series of checkpoint blockades to aid in this process. 
Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) is a homologue of cluster of 




has a higher affinity for CTLA-4 than it does for CD28, allowing for CTLA-4 to outcompete 
this activation and pause immune activation. CTLA-4 is constitutively expressed on 
regulatory T cells (Treg), and will become upregulated in T cells after their activation. In 
response, CTLA-4 expression will inhibit T cell activation and the efficacy of an anti-tumor 
response. 
Programmed death protein-1 (PD-1), on the other hand, is a CD28 and CTLA-4 
homologue that is induced on normal, activated T cells. PD-1 promotes apoptosis in 
activated T cells within the periphery, and it reduces apoptosis of Treg cells(194).  When 
these checkpoints fail, an armory of specialized cells will eliminate tumor-promoting 
cells(199).  
Along with dysfunctional antigen presenting cells, the tumor itself actively modifies 
the tumor microenvironment to suppress effector T cells and induce inflammation. As a 
result, the tumor microenvironment contains a robust population of regulatory T cells and 
myeloid-derived suppressor cells (MDSC), which suppress innate and adaptive 
responses(200).  
With the overexpression of a number of checkpoint molecules, the tumor evades 
T cell recognition. Chronic exposure of the cancer cells to antigen leads to PD-1 
upregulation and lead to T cell exhaustion(194). Additionally, programmed death ligand-
1 (PD-L1) is the ligand of PD-1 and is found upregulated in tumors. When PD-L1 is 
expressed, T cells are prevented from recognizing tumor-specific antigens. In cancer, 
high levels of PD-L1 in the tumor have been correlated with poor prognosis and 
progression(201). Dysregulation of immune checkpoint blockade pathways can lead to 




immunotherapies have been developed to target checkpoint signaling axes.  
1.4.4 Current challenges in monitoring vaccine immunotherapy 
 Immunotherapy has dramatically increased cancer survival and response rates for 
the past few decades. This is possibly due to its potential to achieve long-term disease 
control in a significant population of patients as compared to targeted therapies. 
Additionally, tumor progression while on immunotherapy peaks later combined with a 
median duration of response spanning up to years. Unfortunately, the mechanism behind 
this long-term response is unclear, and a strict definition of clinical endpoints is lacking.  
 The most commonly used clinical guidelines defining tumor response to 
immunotherapy come from the immune-modified response evaluation criteria in solid 
tumors (imRECIST). This criteria was adapted from response criteria in solid tumors 
(RECIST), since immunotherapy can produce unconventional responses and overall 
survival benefits that were not captured by RECIST(202). Criteria for imRECIST define 
tumor burden as unidimensional with up to five target lesions and two per organ. New 
lesions do not categorically represent progressive disease (PD), and measurable new 
lesions are then incorporated into the total tumor burden. Non-target lesions do not define 
PD, and contribute to definition complete response. PD can be negated by subsequent 
non-PD after 4 weeks from the first documented tumor. Additionally, best response may 
occur after any number of PD assessments(202).  
 For vaccines response monitoring, in particular, a few immunodynamic endpoints 
have been defined, depending on the vaccine type(203). For dendritic cell vaccines, T 
cell response post vaccination in the tumor via IHC is a standard measurement. 




and HLA-DR calculated as a ratio of pre/post scores are also encouraged. For non-cell 
based vaccines, peripheral blood mononuclear cells (PMBCs) are characterized. T cell 
receptor repertoire analysis Flow cytometry is used to quantify and phenotype the T cell 
response, and is a highly quantitative, reproducible, and standardized test(204). T cell 
functions are calculated through flow cytometry of perforin, granzyme, and intracellular 
cytokine expression. Additionally, ELISPOT can be used to assess functionality after 
antigen-specific stimulation, but is limited by lack of reproducibility and requires a 
knowledge of antigens to be tested(205). Whole T cell repertoire through CDR3 
spectratyping and next generation sequencing is now being used to assess T cell 
diversity(206). This method does not require an a priori knowledge of antigens and can 
be performed with less than 1 mL of whole blood. While these methods all provide insight 
into the immune system after vaccination, they require tissue or blood samples from the 
patient, and do not recapitulate events within the entire tumor microenvironment in situ in 
the analysis. Furthermore, site monitoring of the immune response still remains of critical 
consideration in the field of immunotherapy, and molecular imaging techniques have been 
employed. 
 ImmunoPET imaging has been targeting immune biomarkers CTLA-4, PD-1, 
CD47, CD11b, T cell receptor, CXCR4, B7-H3, granzyme B, CD3+ T cells and IFN-γ in 
various preclinical studies(207,208). 89Zr- and 64Cu- labelled PD-L1(209) and 89Zr-
MPDL3280A (NCT02453984) PET tracers are in clinical development for imaging PD-L1. 
First-in-human PD-L1 imaging studies demonstrated heterogeneous tumor uptake 
among tumors with minimal PD-L1 expression through IHC, coupled with high 




feasibility, although improvements are necessary to improve background uptake and 
expression correlating to imaging results. 18F-Clofarabine (CFA) is in development for 
monitoring immune cell proliferation through deoxycytidine kinase imaging(211). T cell 
activation through the deoxyguanosine pathway is in trials using 18F-D-
arabinofuranosylguanine (AraG) PET imaging(212). CD8+ T cells are imaged through 
89Zr/64Cu-anti-CD8(213,214) and 89Zr-IAB22M2C PET imaging(58). 
 The potential for imaging provides a unique opportunity to directly monitor immune 
responses within the tumor microenvironment before tumor shrinkage and response can 
be verified through other means. Immunotherapy regimens are still being optimized, and 
significant efforts have been made to identify and validate predictive biomarkers to aid in 
treatment decisions. These biomarkers could be used alone or in combination imaging, 
and additionally with ex vivo analysis and validation throughout treatment. 
1.5 Specific aims and summary of research 
The studies outlined in this dissertation have been partitioned into three specific 
aims. In the first aim found in Chapter 2, titled “Monitoring Src Status after Dasatinib 
Treatment in HER2+ Breast Cancer with 89Zr-trastuzumab PET imaging”, I explored the 
relationship between Src and HER2 is explored as is the ability of 89Zr-trastuzumab to 
monitor changes in HER2 after Src treatment. In this study, upon abrogation of Src 
signaling with dasatinib, an increase in 89Zr-trastuzumab binding and uptake was 
observed in in vitro cell studies and in vivo animal studies of trastuzumab-sensitive (BT-
474) and trastuzumab-resistant (JIMT-1) lines. The uptake to standard 18F-FDG imaging 
was compared to find that this metabolic tracer failed to distinguish differences in tumor 




pSrc (Y416) abrogation and pHER2 (Y1221/1222) expression, and 89Zr-trastuzumab 
uptake. 
In the second aim, described in Chapter 3, entitled “Using 89Zr-cetuximab PET 
imaging to visualize membrane EGFR expression following dasatinib treatment in TNBC”, 
the ability of 89Zr-cetuximab was explored to measure changes in EGFR localization after 
dasatinib treatment, and if any correlation can be made with an improved response to 
combination dasatinib and cetuximab treatment. Using TNBC cell lines MDA-MB-231 
(KRAS mutant), MDA-MB-468 (KRAS wild-type-wt), an increase in 89Zr-cetuximab 
binding and internalization was demonstrated after dasatinib treatment, coupled with a 
decrease in both pSrc (Y416) expression, and in nuclear EGFR expression as shown by 
western blots. In vivo studies of using the tumors established from these two cell lines 
including a TNBC patient-derived xenograft (JAX TM00089, KRAS wt), an increase in 
89Zr-cetuximab uptake was demonstrated after dasatinib treatment, with a concomitant 
improvement in treatment responses with combination dasatinib and cetuximab therapy 
in kras wild-type cell lines. Ex vivo validation studies showed a correlation between EGFR 
expression and 89Zr-cetuximab uptake. 
In the final aim found in Chapter 4, titled “Using immunoPET to monitor tumor 
response to immunotherapy”, the ability for 89Zr-labeled anti-IFNγ (89Zr-anti-IFNγ) was 
evaluated to visualize changes in tumor uptake after a HER2/neu DNA vaccine that 
induces an active T-cell response against rat neu antigen. In transgenic mice and mice 
bearing syngeneic tumors, a significant increase was observed in 89Zr-anti-IFNγ uptake 
within the tumor after vaccination, with a low uptake in secondary lymphoid organs 




IFN-γ production and CD8 T-cell infiltrates within the tumor.  
As is pertains to this thesis, ways to monitor response to targeted therapy and 
immunotherapies are warranted. These results will provide fundamental insights into the 






CHAPTER 2: MONITORING SRC STATUS AFTER DASATINIB TREATMENT IN 
HER2+ BREAST CANCER WITH 89ZR-TRASTUZUMAB PET IMAGING 
 
This chapter was adapted in full from “Monitoring Src status after dasatinib 
treatment in HER2+ BC with 89Zr-trastuzumab PET imaging” by Brooke McKnight and 
Nerissa T. Viola-Villegas, originally published in Breast Cancer Research and used with 
their permission. 
2.1 INTRODUCTION 
The human epidermal growth factor receptor 2 (HER2) has become a critical 
therapeutic target with trastuzumab (Herceptin®) as the mainstream, first-in-line standard 
of care in HER2-positive BC patients(215,216). Unfortunately, response rates to HER2-
targeted therapy remain dismal due to acquired and de novo resistance, which in part, 
can be attributed to alterations in receptor tyrosine kinases (RTKs)(189), and downstream 
signaling transduction pathways, such as Src(217,218).  
Src is a non-receptor tyrosine kinase expressed ubiquitously that interacts with 
several RTKs(158). Its activation enhances cellular migration and survival(149). It has 
been shown that the hyperactivation of Src leads to HER2 stabilization and vice 
versa(157), establishing a functional relationship between the two oncogenes(157). This 
was reported in a study by Tan et al. wherein Src abrogation concomitantly led to 
decreased HER2 levels within 7-14 days of treatment with a Src inhibitor, PP2 in 
vitro(157). Thus, Src is implicated as a key molecule in resistance to trastuzumab therapy, 
making this signaling axis an attractive target for inhibition.  
Dasatinib (Sprycel®) is a Src and BCR/ABL tyrosine kinase inhibitor and was FDA-
approved for leukemia in 2006(219). Preclinical data reported by Seoane et al. 




attenuated phosphorylated levels of Src, ERK and AKT in HER2+ BC(220). These 
preclinical findings were validated in a prospective phase I-II trial exploring combinatorial 
efficacy and safety of dasatinib, trastuzumab and paclitaxel in patients with BC(221). 
Monitoring of tumor response to this drug cocktail was conducted through 
immunohistochemistry (IHC) analysis of patients’ skin samples. However, better ways to 
non-invasively monitor tumor response can be achieved by exploring the direct causal 
relationship between HER2 and Src.  
In this study, the potential of 89Zr (t1/2 ~ 3.27 d) labeled trastuzumab was 
investigated as a surrogate tool to monitor biologic effects of dasatinib (Sprycel) treatment 
in HER2+ BC. First evaluation the specificity of 89Zr- trastuzumab in BT-474 
(HER2+/ER+/PR-), JIMT-1 (HER2+, trastuzumab resistant), and MDA-MB-468 (triple 
negative) cell lines was evaluated with its ability to resolve changes in HER2 expression 
during dasatinib treatment. Next, the utility of 18F-FDG and 89Zr-trastuzumab as a 
predictive imaging tool was examined using the same group of mice-bearing BT-474 and 
JIMT-1 tumors treated with dasatinib. After imaging, HER2 PET uptake was correlated to 
changes in tumor volume, immunoblots, and immunohistochemistry.  
2.2 RESULTS 
2.2.1 Characterization of 89Zr-trastuzumab 
Radiolabeling yields of >95% were obtained with >97 % purity after purification via 
spin column. A specific activity of 2.98 ± 0.2 mCi/mg (20.9 ± 5.6 Bq/µmol) was 
established. The labeled antibody retained immunoreactivity towards HER2 with 85% 




Figure 12. 89Zr-trastuzumab retains immunoreactivity in BT-474. Immunoreactivity of 
89Zr-trastuzumab showed retained reactivity with r2 = 0.96. 
 
2.2.2 In vitro treatment studies with dasatinib  
BT-474 (Fig. 13A) and JIMT-1 (Fig. 13B) cells were treated with increasing 
concentrations of dasatinib to achieve an IC50 value for 72 h post-treatment. IC50 value of 
1.3 ± 0.12 µM and 0.22 ± 0.09 µM were achieved for BT-474 and JIMT-1 respectively. 
BT-474 and JIMT-1 cells were treated with dasatinib for 6-48 h and western blots were 
performed on treated and untreated cell lysates to observe protein expression. In BT-474 
cells (Fig. 13C), there was no change in total HER2 or total Src protein expression upon 
treatment with dasatinib. After 6 h of exposure to dasatinib, total abrogation of pSrc (Y416, 
directly associated with dasatinib Src tyrosine kinase activity(222)) and pHER2 
(Y1221/1222, autophosphorylation site) were observed. In JIMT-1 cells (Fig. 13D), 
attenuation of pHER2 (Y1221/1222) after 24 h and pSrc (Y416) activity after 6 h was 
displayed post-dasatinib treatment. There was no change in total HER2 or Src protein 





Figure 13. Dasatinib treatment decreases pSrc (Y416) and pHER2(Y-1221) protein 
levels in vitro. BT-474 (A) or JIMT-1 (B) cells were treated with increasing concentrations 
of dasatinib for 72 h to achieve IC50 values of 1.3 ± 0.12 µM and 0.8 ± 0.02 µM, 
respectively. BT-474 cells (C) and JIMT-1 (D) were treated with IC50 dasatinib up to 48 h 
and western blots were performed for HER2, Src, pSrc (Y416), and pHER2 (Y1221/1222). 
Densitometry results are shown as the ratio of target protein/GAPDH. 
 
Next, the ability of HER2 to internalize trastuzumab after dasatinib timecourse 
treatment was investigated using 89Zr-trastuzumab (Fig. 14). A steady decrease in 89Zr-
trastuzumab internalization was exhibited by both BT-474 and JIMT-1. Internalization of 
89Zr-trastuzumab in untreated BT-474 was measured at 10.37 ± 1.62% without dasatinib 




treatment with ~7.68 ± 0.53% (p = 0.02), and 7.42 ± 0.74% (p = 0.03) respectively. At 48 
h, only ~4.78 ± 0.42% (p = 0.006) of the radiotracer was found intracellularly. JIMT-1 cells 
also showed a decrease in internalization upon treatment. From  2.6 ± 0.25% internalized 
in untreated cells, bound activity was reduced to 1.22 ± 0.10% (p = 0.009) after 24 h, and 
0.17 ± 0.5% (p < 0.0001) after 48 h of treatment. No significant reduction in internalized 
radiotracer was observed after 6 h of dasatinib exposure (1.96 ± 0.46%, p = 0.10). 
 These results are similar to the amount of total membrane-bound HER2 present 
extracellularly (and thus, available for tracer targeting) during dasatinib treatment as 
represented by the total amount of 89Zr-trastuzumab bound (Fig. 14). Compared to 
untreated BT-474 cells with 14.10 ± 1.22% bound radiotracer, a decrease was observed 
in treated groups after dasatinib exposure for 6 h (11.79 ± 1.00%, p = 0.0854) and 24 h 
(11.42 ± 2.04%, p = 0.038). Further reduction was observed after 48 h with 8.88 ± 1.44% 
(p = 0.0002). In JIMT-1 cells, a similar trend was observed with lower 89Zr-trastuzumab 
binding in groups treated for 6 h (2.46 ± 1.02%, p = 0.9578), 24 h (1.26 ± 1.00%, p 




Figure 14. 89Zr-trastuzumab binding and uptake decreases upon dasatinib 
treatment. Internalization and binding assays of 89Zr-trastuzumab on BT-474 and JIMT-
1 cells treated with dasatinib IC50 from 0-48 h showed a decrease in probe internalization 
and binding over time  
 
 These results are in good agreement with the western blot findings. In BT-474, an 
abrogation of pHER2(Y1221/1222) was observed after 6 h dasatinib treatment. Coupled 
with the internalization assays, the same decrease in tracer internalization was observed 
after 6 h. Similarly, in JIMT-1, a decrease in pHER2 after 24 h dasatinib treatment was 
observed, which is where drop off in internalization of the tracer occurs. These results 
suggest that there is an association between dasatinib treatment and a decrease in 
internalization, which results in a reduction in total cellular accumulation (89Zr-






Figure 15. 89Zr-trastuzumab binding and uptake decreases upon dasatinib 
treatment. Treatment and imaging scheme illustrate treatment of tumors for 7 d and/or 
14 d with dasatinib followed by PET imaging with 18F-FDG. 89Zr-trastuzumab was 
administered a day after with imaging acquired 48 h p.i. Tx = Treatment. 
 
2.2.3 Validation of 89Zr-trastuzumab specificity to HER2 
From in vitro studies using BT-474 (HER2+/ER+), JIMT-1 (HER2+/ER-), and MDA-
MB-468 (HER2-/ER+) cells, co-administration of 25-fold unlabeled trastuzumab exhibited 
lower binding of 89Zr-trastuzumab in HER2+ cell lines and did not change binding in MDA-
MB-468 HER2- cell line (Fig. 16A). In BT-474, there was a 6-fold decrease of 89Zr-
trastuzumab binding in trastuzumab blocked cells compared to control (1.07 ± 0.24% vs. 
6.64 ± 1.14%, p < 0.0001). JIMT-1 cells exhibited a 2-fold decrease in 89Zr-trastuzumab 
binding in 25-fold trastuzumab blocked cells compared to control (0.65 ± 0.18 vs. 1.46 ± 
0.24, p = 0.0007). MDA-MB-468 cells did not exhibit a difference in 89Zr-trastuzumab 
binding between 25-fold blocked cells and control (0.71 ± 0.40 vs. 1.11 ± 0.56, p = 0.34).  
 Mice bearing BT-474, JIMT-1, or MDA-MB-468 xenografts were imaged with 89Zr-
trastuzumab at 48 h p.i. (Fig. 16B-C). MDA-MB-468 tumors exhibited the lowest uptake 
of 3.9 ± 0.6 %ID/g, compared to BT-474 (17.9 ± 2.2 %ID/g, p < 0.001) and JIMT-1 (7.7 ± 
0.6 %ID/g, p < 0.001) tumors. Interestingly, there was significantly less 89Zr-trastuzumab 




Figure 16. 89Zr-trastuzumab is specific for HER2. BT-474, JIMT-1, and MDA-MB-468 
cells were incubated with 100 ng 89Zr-trastuzumab alone or co-incubated with 25-fold 
unlabeled Trastuzumab before being lysed and radioactivity measured using a gamma 
counter (A); nude mice bearing MDA-MB-468, BT-474, or JIMT-1 tumors were imaged 
with 89Zr-trastuzumab 48 h p.i. (B); tumor ROIs showing significant uptake in HER2+ 
tumors, but no uptake in MDA-MB-468 HER2- tumors (C). 
 
 Tissue distribution addressed concerns against enhanced permeation retention 
(EPR) effect. In BT-474 tumor, 89Zr-trastuzumab uptake in the tumor was 16.01 ± 3.78 
%ID/g, which is significantly higher than an isotype-matched IgG control (1.02 ± 0.87 
%ID/g, p = 0.0002) (Fig. 17, Table 10). 89Zr-trastuzumab had an average tumor uptake of 
4.13 ± 2.36 %ID/g (Fig. 17, Table 11) in JIMT-1 tumors, whereas the non-specific IgG 
control probe exhibited a significantly lower tumor accumulation of 0.79 ± 0.24 %ID/g  (p 




Figure 17. 89Zr-trastuzumab tumor uptake compared to isotype matched control. 
Mice bearing BT-474 and JIMT-1 tumors were injected with 89Zr-IgG or 89Zr-trastuzumab 
and tumors were removed 48 h p.i. and measured using a gamma counter. In both cell 










 Mean  S.D. Mean  S.D. 
Blood 2.39 ± 1.14 1.71 ± 1.01 
Tumor 16.10 ± 3.79 1.02 ± 0.87 
Heart 3.17 ± 1.43 0.50 ± 0.21 
Lungs 13.37 ± 9.79 0.50 ± 0.28 
Liver 9.27 ± 5.56 9.12 ± 2.66 
Kidneys 4.53 ± 3.85 5.27 ± 2.47 
Stomach 1.86 ± 1.23 0.59 ± 0.30 
Intestines 3.74 ± 0.80 3.44 ± 1.41 
Spleen 8.15 ± 3.75 0.54 ± 0.35 
Pancreas 1.76 ± 1.20 0.21 ± 0.20 
Brain 0.25 ± 0.29 0.15 ± 0.04 
Bone 10.34 ± 3.26 0.03 ± 0.01 
Muscle 0.33 ± 0.18 0.06 ± 0.02 







 Mean  S.D. Mean  S.D. 
Blood 6.69 ± 2.53 1.23 ± 0.65 
Tumor 4.13 ± 2.36 0.08 ± 0.02 
Heart 2.20 ± 0.92 0.39 ± 0.18 
Lungs 3.01 ± 2.25 0.65 ± 0.44 
Liver 4.70 ± 1.46 9.43 ± 6.96 
Kidneys 4.49 ± 1.28 5.10 ± 1.59 
Stomach 1.13 ± 0.46 0.34 ± 0.17 
Intestines 3.79 ± 1.07 3.08 ± 0.35 
Spleen 2.79 ± 1.38 0.36 ± 0.16 
Pancreas 0.93 ± 0.38 0.12 ± 0.06 
Brain 0.33 ± 0.19 0.12 ± 0.04 
Bone 0.65 ± 0.40 0.02 ± 0.01 
Muscle 0.33 ± 0.17 0.04 ± 0.04 
Table 11. 89Zr-trastuzumab 89Zr-IgG biodistribution in JIMT-1 tumors. 
2.2.4 In vivo monitoring of tumor response to dasatinib  
Mice bearing palpable BT-474 tumors were dosed with dasatinib for 7 and 14 days 
and imaged with 18F-FDG and 89Zr-trastuzumab (Fig. 18). Tumor uptake of 18F-FDG was 
not statistically different between untreated mice (3.60 ± 1.51% ID/g) and those treated 
with dasatinib for 7 d (3.86 ± 0.59 %ID/g, p = 0.99) and 14 d (4.63 ± 0.21 %ID/g, p = 0.80) 
(Fig. 19A). In comparison, 89Zr-trastuzumab exhibited a significant decrease in tumor 
accumulation in both treated groups (7 d: 11.05 ± 2.10 %ID/g, p < 0.0001, and, 14 d: 9.2 




No significant difference in probe uptake was observed between 7 and 14 d treated 
cohorts (p = 0.3925) (Fig. 19C). A correlation between changes in tumor volumes 
measured prior and after treatment vs. 89Zr-trastuzumab VOI PET uptake displayed a 
significant positive correlation (r = 0.85, p = 0.001) (Fig. 19D) wherein a decrease in tumor 
volume matched a lower PET readout. 
 
Figure 18. 89Zr-trastuzumab binding and uptake decreases upon dasatinib 
treatment. Treatment and imaging scheme illustrates treatment of tumors for 7 d and/or 
14 d with dasatinib followed by PET imaging with 18F-FDG. 89Zr-trastuzumab was 





Figure 19. 89Zr-trastuzumab PET imaging predicts tumor response to treatment in 
BT-474 xenografts. Untreated (left) and treated BT-474 tumors for 7 d (middle) or 14 d 
(right) with 75 mg/kg dasatinib were imaged with FDG-PET (A). In the same group of 
mice, PET imaging with 89Zr-trastuzumab demonstrated attenuated tracer accumulation 
in treated groups compared to control (B). Tumor VOIs demonstrated lower tumor uptake 
of 89Zr-trastuzumab in treated groups compared to control; no observed changes were 
detected by FDG in both control and treated groups (C). % change in tumor volume during 
treatment correlated with 89Zr-trastuzumab uptake (D). T = tumor, L = liver. *** denotes p 
< 0.001. 
 
In JIMT-1 tumor bearing mice, FDG-PET did not distinguish untreated tumors (3.81 
± 0.78 %ID/g) vs. dasatinib-treated groups (7d: 3.36 ± 0.89 %ID/g, p = 0.7338; 14 d: 3.20 
± 1.37 %ID/g, p = 0.6126) (Fig. 20A). Using the same mice, tumor uptake of 89Zr-
trastuzumab displayed VOIs of 8.04 ± 0.71 %ID/g for control; a two-fold decrease in 
uptake after 7 d (3.88 ± 1.47 %ID/g, p < 0.0001) and 14 d (4.45 ± 1.23 %ID/g, p < 0.0001) 




was no observed difference in tracer accumulation observed between treated cohorts (p 
= 0.7120) (Fig. 20C). Changes in tumor volumes displayed a direct, positive correlation 
with 89Zr-trastuzumab PET uptake (r = 0.82, p = 0.0002) (Fig. 20D).  
 
Figure 20. 89Zr-trastuzumab PET imaging predicts tumor response to treatment in 
JIMT-1 xenografts. Untreated (left) and 7 d (middle) or 14 d (right) treated JIMT-1 tumors 
imaged with FDG (A). The same group of mice imaged with 89Zr-trastuzumab after 48 h 
p.i. (B). VOIs drawn on the tumors displayed lower accumulation of 89Zr-trastuzumab in 
treated groups compared to control but no change in FDG-PET tumor uptake was 
observed across all cohorts (C). % Change in tumor volume correlated with 89Zr-
trastuzumab uptake (D) T = tumor, L = liver. *** denotes p < 0.001. 
 
2.2.5 Ex Vivo analysis of BT-474 and JIMT-1 Tumors 
After imaging, tumors were removed for ex vivo validation of the PET readout. 
From the immunoblot analysis, BT474 tumors showed a moderate decrease in total Src 
levels upon treatment with dasatinib, whereas its activity was mitigated by 2.6-fold as 




there is a decrease in total HER2 via densitometry after 7 d and 14 d treatments (Fig. 
21A). A positive correlation between pSrc (Y416) (r = 0.70, p = 0.025) (Fig. 21B) and 
pHER2 (r = 0.64, p = 0.046) (Fig. 21C) (measured by densitometry) against tumor VOI 
values for BT-474 was observed. 
Figure 21. Ex vivo validation on excised BT-474 tumors confirm PET uptake. 
Western blots were performed for HER2, Src, and pSrc (Y416) expression using BT-474 
tumor lysates (A); a plot of the pSrc (Y416) densitometry shows a linear relationship with 
89Zr-trastuzumab PET uptake (B); a plot of the pHER2 (Y1221) densitometry vs. tumor 
VOI shows a positive linear relationship with 89Zr-trastuzumab PET uptake (C). 
 
Treated and control JIMT-1 tumors did not show a difference in total HER2 or Src 
expression, however, a noticeable decrease in both pSrc and pHER2 after 7 and 14 d 




between pSrc (Y416) (r = 0.68, p = 0.022) and 89Zr-trastuzumab tumor VOI was achieved 
(Fig. 22B). A direct relationship between dephosphorylated HER2 and tracer uptake in 
the tumor was also demonstrated (r = 0.63, p = 0.037) (Fig. 22C). 
 
Figure 22. Ex vivo validation on excised JIMT-1 tumors confirm PET uptake. 
Western blots were performed for HER2, Src, and pSrc (Y416) expression using JIMT-1 
tumor lysates (A); a plot of the pSrc (Y416) densitometry shows a linear relationship with 
89Zr-trastuzumab PET uptake (B); a plot of the pHER2 (Y1221) densitometry vs. tumor 
VOI shows a positive linear relationship with 89Zr-trastuzumab PET uptake (C). 
 
IHC was performed to visualize subcellular localization of HER2 and pSrc (Y416) 
in excised tumors. Unmodulated BT-474 tumors showed strong positive membranous 
HER2 staining (Fig. 23A, top left panel), whereas, predominant cytoplasmic HER2 




right). Lower pSrc (Y416) staining was observed in treated tumors (Fig. 23A, bottom right) 
compared to control (Fig. 23A, bottom left). Control JIMT-1 tumors exhibited lower 
expression of membrane-localized HER2 (Fig. 23B, top left) compared to BT-474 but 
translocation to cytoplasmic regions was observed in treated sections (Fig. 23B, top right). 
Higher pSrc (Y416) staining is displayed in control (Fig. 23B, bottom right) versus 
dasatinib treated tumor sections (Fig. 23B, bottom left). 
 
Figure 23. Immunohistochemistry on excised BT-474 and JIMT-1 tumors show 
HER2 and pSrc (Y416) changes. IHC (40× magnification) was performed on excised 
BT-474 tumors (A) and JIMT-1 (B) showing HER2 (top) and pSrc (Y416, bottom) 





Trastuzumab has been the standard of care for two decades for HER2+ BC(134). 
Unfortunately, about half of patients with HER2-overxpressing BC do not respond to 
trastuzumab due to de novo and acquired resistance mechanisms(223). The non-
receptor tyrosine kinase Src was shown to be a key modulator of trastuzumab response, 
and is an important downstream node of multiple trastuzumab resistance 
pathways(149,158,218,223,224). Targeting Src with dasatinib in vitro re-sensitized 
trastuzumab-resistant cell lines, suggesting this pathway as a strategy to overcome 
resistance(158). Additionally, patients with high levels of phosphorylation of Src at the 
Y416 residue have presented a lower clinical response rate and higher progressive 
disease after trastuzumab treatment, compared to those with lower pSrc (Y416) levels, 
suggesting that pSrc activation is correlated with trastuzumab resistance(225).  
Clinical trials (NCT01306942, NCT00566618, and NCT00820170) are currently 
examining dasatinib as part of a multicombinatorial treatment in BC. Previous studies 
have focused on monitoring dasatinib response by radiolabeling dasatinib itself(226). This 
method has its limitations, since this can potentially miss functional effects upstream or 
downstream of the Src signaling pathway. Previous studies have demonstrated the 
relationship of Src and HER2 where it is shown that hyperactivated Src is stabilized by 
aberrant HER2 signaling, and one study in particular demonstrated that modulating c-Src 
with PP2 in vitro decreased HER2 levels after 7 days of treatment and abrogated it 
completely after 14 days of treatment(157,227). Thus, HER2 PET as a surrogate 
predictive marker of dasatinib treatment is worth investigating with 89Zr-trastuzumab PET 




of response to other targeted treatment (NCT01081600 for AUY922 HSP90 inhibitor, 
NCT01565200 for T-DM1 ).  
Previous studies have stated that using 89Zr-trastuzumab PET imaging to monitor 
response to therapy would only be feasible if the drug is directly acting on HER2(59). 
Using 89Zr-trastuzumab as a surrogate marker of targeted inhibition of effector molecules 
downstream of the HER2 signaling pathway has been conceptually proven, for example 
with Hsp90 inhibition(37). To the best of our knowledge, this is the first study that 
demonstrated the potential of 89Zr-trastuzumab PET to monitor Src response to dasatinib 
treatment. Specifically, we have shown that 89Zr-trastuzumab detects lower membrane 
HER2 expression with concomitant internalization of HER2 after 6 h (BT-474) or 48 h 
(JIMT-1) dasatinib treatment, as shown by our internalization assays. The lower 
internalization was coupled with a lower total HER2 present on the cell surface, confirmed 
by 89Zr-trastuzumab binding experiments and western blots of pHER2(Y1221/1222), 
which activates HER2 receptor activation. From our in vivo studies, 89Zr-trastuzumab 
detected changes in HER2 expression upon inhibition of functional Src, where standard-
of-care FDG-PET imaging has failed to detect differences in tumor uptake after dasatinib 
treatment. Importantly, the PET uptake directly correlated with tumor regression.  The 
PET results were histologically validated with a concomitant decrease in membranous 
HER2 staining in treated groups coupled with the abrogation of pSrc (Y416) staining. 
Furthermore, western blot analysis probing for functional Src activity exhibited a direct 
relationship with the HER2 PET readout.  It is worth noting that our studies are limited to 




Src in HER2+ BC still warrants further investigation.  
In conclusion, 89Zr-trastuzumab can potentially delineate changes in Src activity in 





CHAPTER 3: USING 89ZR-CETUXIMAB PET IMAGING TO VISUALIZE MEMBRANE 
EGFR EXPRESSION FOLLOWING DASATINIB TREATMENT IN TNBC 
 
3.1 INTRODUCTION 
TNBC accounts for 20% of all diagnosed BC and lack of therapeutic targets 
(ER/PR/HER2) makes it more difficult to treat, resulting in chemotherapies such as taxane 
or anthracycline as the mainstay standard of care(229). While many TNBC patients 
initially respond to chemotherapy, the high rate of recurrence and progression makes it a 
far more aggressive disease with worse prognosis compared to other subtypes.  
 Gene expression profiling studies identified EGFR as a potential biomarker 
indicating possible treatments due to its overexpression in TNBC(230,231). A number of 
EGFR-targeted therapies that were previously approved for other cancer types are 
currently explored for TNBC, including monoclonal antibodies (panitumumab and 
cetuximab) and small molecule inhibitors (gefitinib, erlotinib, and afatinib)(232). 
Unfortunately, achieving significant response rates in the clinic were dismal(233,234) 
possibly due to the lack of biomarkers to select appropriate patients who would be 
predited to respond. One explanation may be attributed to the receptor’s nuclear 
translocation, diminishing drug targeted delivery to cell-surface receptors. nEGFR acts as 
a transcription factor regulator  involved in tumorigenesis(235,236). Interestingly, the 
expression of nEGFR has been correlated with poorer outcomes in many 
cancers(82,237,238), and resistance to anti-EGFR therapies, including 
cetuximab(168,239). Previous studies have shown that Src Family Kinase (SFK) 
inhibition with dasatinib blocks nEGFR translocation, transporting EGFR to the plasma 





Studies developing 89Zr(t1/2 ~ 3.27 d) labeled cetuximab (Erbitux®) as a positron 
emission tomography (PET) tracer have been reported. This EGFR-specific imaging 
probe is currently in clinical trials to select cancer patients who may benefit from 
cetuximab treatment in many cancer types(241–243). To date, 89Zr-cetuximab has shown 
promise in visualizing tumors expressing EGFR, and could be used to monitor EGFR 
receptor expression and steer individualized treatments(244). 
 In this aim, it was hypothesized that 89Zr-cetuximab could be used as a tool to 
monitor membrane EGFR expression after dasatinib treatment in TNBC. 89Zr-cetuximab  
specificity was evaluated in EGFR-positive TNBC cell lines MDA-MB-231 (KRAS mutant) 
and MDA-MB-468 (KRAS wild type (wt)) and was compared against low EGFR-
expressing TNBC MDA-MB-453 (KRAS mutant) cells. After establishing the tracer’s 
specificity, its potential to assess changes in membranous EGFR density was 
investigated in both EGFR-positive TNBC xenografts post-treatment with dasatinib 
through in vitro internalization assays and western blots. An EGFR-positive, Kras wt 
TNBC patient derived xenograft (PDX, JAX TM-00089) was also investigated for ex vivo 
treatment studies. Validation of 89Zr-cetuximab PET was conducted using western blots, 
immunohistochemistry (IHC) and autoradiography. 
3.2 RESULTS 
3.2.1 Radiolabeling and characterization of 89Zr-cetuximab 
 89Zr-cetuximab radiolabeling yields of >90% were obtained with >95% purity after 




labeled antibody retained immunoreactivity towards EGFR with 74.8 ± 3.4% (Fig. 24) 
n=3). 
Figure 24. 89Zr-cetuximab retains immunoreactivity in MDA-MB-468. A Lindmo assay 
was performed to measure immunoreactivity of 89Zr-cetuximab after modifications and 
shows retained reactivity towards EGFR. 
 
The potential of 89Zr-cetuximab was investigated to assess changes in 
membranous EGFR levels was examined. Using the same treatment scheme, treated 
and untreated cells were incubated with 89Zr-cetuximab at 4 °C to prevent internalization. 
Surface-bound activity increased for both MDA-MB-231 (17.9 ± 3.6% vs. 26.0 ± 3.0%, p 
= 0.042) and MDA-MB-468 (18.9 ± 0.6% vs. 47.3 ± 3.8 %, p = 0.0002) after dasatinib 
treatment (Fig. 25A).   
Internalization rates of 89Zr-cetuximab after dasatinib treatment were investigated 
over time and compared against membrane bound fractions (Fig. 25B). An increase in 
internalization of the tracer after 48 h of drug treatment compared to control was observed 
in MDA-MB-231 cells (16.6 ± 3.3% vs. 26.2 ± 3.7%, p = 0.0002). Similar but more 
pronounced effects were observed in treated MDA-MB-468 cells where internalized 




p < 0.0001) at 24 h and 48 h respectively, compared to control groups (17.9 ± 0.8%). 
Membrane-bound activity for both cell lines did not show a significant difference between 
control and treated groups likely due to internalization. The low-EGFR expressing MDA-
MB-453 demonstrated minimal binding and internalization of the tracer. Collectively, this 
in vitro binding assay suggests that the radiotracer was able to measure higher 








Figure 25. Internalization and uptake of 89Zr-cetuximab. MDA-MB-231 and MDA-MB-
468 cells exposed to dasatinib for 48 h showed higher surface-bound 89Zr-cetuximab 
compared to untreated controls (A); incubation from 8-48 h with dasatinib showed higher 
internalized fractions of the tracer at later time points (B). * denotes p < 0.05, *** denotes 






The low-EGFR expressing MDA-MB-453 demonstrated minimal binding and 
internalization of the tracer (Fig. 26). This suggests that exposure to dasatinib resulted in 
higher membrane-bound EGFR levels available, which can be visualized and quantified 
by 89Zr-cetuximab. Importantly, an increase in cell surface EGFR concomitantly leads to 


















Figure 26. Non-specific tracer uptake in MDA-MB-453. In vitro 89Zr-cetuximab 
internalization in MDA-MB-453 cells (A). Comparison of 89Zr-cetuximab tracer % bound, 
internalized, and total tracer bound and internalized between MDA-MB-231, MDA-MB-
468, and MDA-MB453 cell lines (B). 
 
3.2.2 89Zr-cetuximab is specific for tumors expressing EGFR in vivo 
 The specificity of 89Zr-cetuximab for EGFR was investigated through in vivo 
imaging using mice bearing different EGFR-expressing TNBC tumors (MDA-MB-468 = 
MDA-MB-231 > MDA-MB-453). In MDA-MB-231, tumor uptake was 6.8 ± 1.0 %ID/g at 24 




2.9 %ID/g (Fig. 27A,C). In MDA-MB-468 xenografts, tumor uptake was 7.8 ± 1.3 %ID/g 
at 24 h p.i., 7.6 ± 1.7 %ID/g at 48 h p.i. and 6.8 ± 1.2 %ID/g at 96 h p.i. (Fig. 27B-C). At 
48 h p.i., the optimal time where tumor-to-background was identified, the accumulation of 
89Zr-cetuximab was significantly lower in this control tumor compared to MDA-MB-231 





































Figure 27. In vitro timecourse imaging of 89Zr-cetuximab in MDA-MB-231 and MDA-
MB-468 xenografts. Female nude mice bearing MDA-MB-231 tumors were injected with 
89Zr-cetuximab and imaged from 24-96 h p.i. and tumor VOIs were measured (A). Female 
nude mice bearing MDA-MB-468 tumors were injected with 89Zr-cetuximab and imaged 
from 24-96 h p.i. and tumor VOIs were measured (B). Tumor time activity curve 
demonstrating tumor VOIs throughout imaging time in both cell lines (C). 89Zr-cetuximab 
imaging tumor VOIs in MDA-MB-231 and MDA-MB-468 tumor bearing mice (D). *** 





3.2.3 EGFR expression after dasatinib treatment in vitro 
The half maximal inhibitory concentration (IC50) values of 0.88 ± 0.10 µM (Fig. 28A) 















Figure 28. Achieved IC50 values for MDA-MB-231 and MDA-MB-468 cells.  
MDA-MB-231 (A) or MDA-MB-468 (B) cells were treated with increasing concentrations 
of dasatinib for 72 hours to achieve IC50. 
 
In MDA-MB-231 cell lysates (Fig. 29A) incubated with dasatinib for 48 h, a 
decrease in phospho-EGFR (Y845) from 1.17 to 0.8 and phospho-Src (Y416) levels from 
1.19 to 0.74 as measured by densitometry were observed. Total levels of EGFR remained 






0.69) and pSrc (Y416, 1.87 to 0.83) levels after 48 h exposure to dasatinib was also 
observed. Total EGFR levels changed between untreated and (0.88 to 0.95) treated cells. 
Total Src levels for both cell lines were slightly lower in the treated lysates.   
Next, using the same cell lines, the nuclear (N) and membranous plus cytoplasmic 
(C) localization of EGFR after treatment was investigated(Fig. 29B). In MDA-MB-231, 
there is approximately 21.3% nEGFR present in the untreated samples, which dropped 
to as much as 10-fold upon treatment. Interestingly, total Src protein in the nuclear region 
increased in cells exposed to the drug (43% to 59%). In MDA-MB-468 cells (Fig. 29C), 
64% of EGFR was found in the nucleus of the untreated samples, whereas treatment 
decreased localization to 45%. More nuclear Src i was observed (50%) in the treated cells 
compared to control (41%).  Collectively, these results demonstrates concordance with 






Figure 29. In vitro dasatinib treatment alters EGFR compartmentalization. MDA-MB-
231 (left) and MDA-MB-468 (right) cells were treated with dasatinib IC50 (+) values for 48 
h or left untreated (-). Lysates were evaluated for pEGFR (Y845), EGFR, pSrc (Tyr416), 
and Src (A); nuclear (N) and membrane plus cytoplasmic (C) extracts were collected from 
MDA-MB-231 (B) and MDA-MB-468 (C) cells after 48 h dasatinib treatment or from control 
cells and evaluated for EGFR and Src localization. 
 
3.2.4 In vivo monitoring of membrane EGFR with 89Zr-cetuximab  
Tumor-bearing athymic nude mice treated with either dasatinib or vehicle (Fig. 29) 




cetuximab had higher tumor accumulation in treated vs. control groups (8.7 ± 1.6 %ID/g 
























Figure 30. In vivo 89Zr-cetuximab PET imaging in MDA-MB-231 xenografts. Mice 
bearing MDA-MB-231 tumors were left untreated (left) or treated with dasatinib (right) for 
5 days before undergoing 89Zr-cetuximab PET imaging at 48 h p.i. (A). 89Zr-cetuximab 
tumor VOIs demonstrate higher uptake of the tracer in treated mice compared to control 
(B). * denotes p < 0.05. 
 
Autoradiography of excised tumors demonstrated spatial distribution of the tracer 
with higher focal uptake observed in treated (Fig. 31A, right) vs. control (Fig. 31A, left) 
tumor sections. Immunohistochemistry on serial sections displayed compartmentalization 
of EGFR (Fig. 31B, top) and pSrc (Y416) (Fig. 31B, bottom) levels with (left) and without 






nucleus, whereas after dasatinib treatment an increase in membranous staining of EGFR 
was observed. Cytoplasmic phospho-Src (Y416) staining was observed control tumors 
but staining was abrogated upon treatment.  
Western blot densitometry analysis demonstrated a significant increase in total 
EGFR in treated mice when compared to untreated mice (0.35 ± 0.05 vs. 0.23 ± 0.07, p 
= 0.043) (Fig. 31C, Table 12). Functional EGFR (pEGFR-Y845) was mitigated after 
dasatinib treatment. Based on densitometric ratios of EGFR/GAPDH, a ratio of 0.64 ± 
0.31 was observed in control tumors vs. 0.08 ± 0.16 in treated groups (p = 0.0173)(Table 
12). An almost three-fold decrease in pSrc (Y416) expression was displayed between 
tumors that were given vehicle and dasatinib (1.57 ± 0.554 vs. 0.638 ± 0.06, p = 0.0151). 
Total Src expression was not significantly different between control and dasatinib treated 
tumors (0.498 ± 0.13 vs. 0.583 ± 0.10, p = 0.3406). A positive correlation was achieved 















Figure 31. Ex vivo analysis on MDA-MB-231 tumors. Ex vivo autoradiography (A), 
H&E (B, bottom), and IHC of EGFR (B, top) and pSrc (Y416, B, middle) shows differences 
in tracer localization and expression after dasatinib treatment (right) compared to control 
(left). Western blots of control (left) and dasatinib treated (right) tumors were evaluated 
for pEGFR (Y845), EGFR, pSrc (Y416), and Src (C). Densitometry for EGFR was 









Mean ± S.D. 
Dasatinib 
Mean ± S.D. P-value 
pEGFR (Y845) 0.64 ± 0.31 0.08 ± 0.16 0.02 
EGFR 0.23 ± 0.07 0.35 ± 0.05 0.04 
pSrc (Y416) 1.6 ± 0.55 0.64 ± 0.06 0.02 
Src 0.5 ± 0.13 0.58 ± 0.1 0.34 
Table 12. Densitometry of MDA-MB-231 tumors. 
Treated MDA-MB-468 tumors (Fig. 32A) exhibited an almost two-fold increase in 
89Zr-cetuximab uptake compared to control, untreated tumors (14.25 ± 3.92 %ID/g vs. 











Figure 32. In vivo 89Zr-cetuximab PET imaging in MDA-MB-468 xenografts. Mice 
bearing MDA-MB-468 tumors were left untreated (left) or treated with dasatinib (right) for 
5 days before undergoing 89Zr-cetuximab PET imaging at 48 h p.i. (A). 89Zr-cetuximab 
tumor VOIs demonstrate higher uptake of the tracer in treated mice compared to control 
(B). ** denotes p < 0.01. 
 
Autoradiographic images of excised tumors displayed an increase in tracer uptake 
in dasatinib treated (right) tumors compared to control untreated tumors (left) (Fig. 33A). 






and cytoplasm in untreated tumors, which changed to strong membranous EGFR staining 
after treatment. A close examination of pSrc (Y416) expression (bottom) also showed a 
positive cytoplasmic stain in untreated tumors, which was attenuated in the treated tissue 
sections (Fig. 33B). 
Immunoblots further reinforced the tracer readout. A significant increase in total 
EGFR (0.12 ± 0.03) compared to control tumors (0.05 ± 0.03, p = 0.024) was achieved 
(Fig. 33C, Table 13). Phosphorylation of EGFR at Y845 displayed a decreasing trend 
after dasatinib treatment compared to control (0.07 ± 0.03 vs. 0.11 ± 0.4). We observed 
a two-fold decrease in pSrc (Y416) protein after dasatinib treatment (0.30 ± 0.6 vs. 0.47 
± 0.02, p = 0.006). Similarly, to MDA-MB-231, there was no significant change in total Src 
protein level after dasatinib treatment (0.56 ± 0.08 vs. 0.58 ± 0.12, p = 0.842). 































Figure 33. Ex vivo analysis on MDA-MB-468 tumors. Ex vivo autoradiography (A), 
H&E (B, bottom), and IHC of EGFR (B, top) and pSrc (Y416, B, middle) shows differences 
in tracer localization and expression after dasatinib treatment (right) compared to control 
(left). Western blots of control (left) and dasatinib treated (right) tumors were evaluated 
for pEGFR (Y845), EGFR, pSrc (Y416), and Src (C). Densitometry for EGFR was 
correlated to tumor VOI (D).  









Mean ± S.D. 
Dasatinib 
Mean ± S.D. P-value 
pEGFR (Y845) 0.11 ± 0.04 0.07 ± 0.03 0.12 
EGFR 0.05 ± 0.03 0.12 ± 0.03 0.02 
pSrc (Y416) 0.47 ± 0.01 0.3 ± 0.06 0.01 
Src 0.56 ± 0.08 0.58 ± 0.12 0.84 
Table 13. Densitometry of MDA-MB-468 tumors. 
3.2.5 Effects of combinatorial dasatinib and Cetuximab therapy 
 The addition of cetuximab in combination with dasatinib after neoadjuvant Src 
inhibition was next explored. In this longitudinal study, mice treated with dasatinib prior to 
PET imaging were further stratified into two arms after PET imaging. One group received 
continuous dasatinib treatment while a second group received dasatinib plus cetuximab 
(Fig. 34). The same control group of mice used in the imaging scan was monitored for 
tumor progression throughout the study. 
 
Figure 34. Treatment Scheme. Mice were implanted with MDA-MB-231 or MDA-MB-
468 tumors and allowed to acclimate for 10 days before either receiving dasatinib (50 
mg/kg for 5 d) or left untreated. Mice then underwent 89Zr-cetuximab PET imaging 48 h 
p.i. of the tracer. After imaging, dasatinib treated mice were stratified into treatment 
groups of dasatinib only (50 mg/kg for 5 d) or dasatinib (50 mg/kg for 5 d) plus cetuximab 
(0.2 mg i.p. 2x/week). 
 
In MDA-MB-231 tumor bearing mice, no tumor response benefit was achieved in 




and % change in tumor volume after treatment (Fig. 35B) (r = 0.095, p = 0.735). 
  On the other hand, a synergistic effect was observed in MDA-MB-468 tumors (p 
= 0.021) receiving the combinatorial therapy compared to dasatinib treatment alone (Fig. 
35C). An examination of the correlation between tumor VOI and % change in tumor 
volumes revealed a negative correlation wherein higher accumulation of 89Zr-cetuximab 
in the tumor resulted in slower growth. (r = -0.62, p = 0.013)(Fig. 35D). 
 
Figure 35. Tumor response to combination treatment or cetuximab alone. Tumor 
volume (mm3) of MDA-MB-231 tumors undergoing treatment for 30 days (A). Correlation 
between 89Zr-cetuximab tumor VOI (%ID/g) and percent change in tumor volume after 
treatment regimen in MDA-MB-231 (B). Tumor volume (mm3) of MDA-MB-468 tumors 
undergoing treatment for 30 days (C). Correlation between 89Zr-cetuximab tumor VOI 
(%ID/g) and percent change in tumor volume after treatment regimen in MDA-MB-468 
(D). 
  
A.  B.  




3.2.6 Evaluating changes in EGFR localization after Dasatinib Treatment in TNBC 
PDX 
The effects of dasatinib treatment and the potential of 89Zr-cetuximab to monitor 
changes in membranous EGFR density in an EGFR-expressing TNBC PDX tumor model 
was investigated. Palpable tumors dosed with dasatinib for 5 days had a significantly 
higher tracer uptake compared to the control untreated arm (7.27 ± 2.3 %ID/g vs. 4.48 ± 





Figure 36. 89Zr-cetuximab PET imaging in TM00089 PDX tumors. Mice bearing 
TM00089 PDX xenograft tumors were treated with dasatinib (50 mg/kg for 5 d) or left 
untreated before imaging with 89Zr-cetuximab at 48 h p.i. (A). 89Zr-cetuximab tumor VOIs 
demonstrate higher uptake of the tracer in treated mice compared to control (B). 
 
Tumors were removed post-imaging for autoradiography and IHC. 89Zr-cetuximab 
tracer distribution increased in the dasatinib treated tumor (Fig. 37A, right), compared to 
control tumor (Fig. 37A, left). Immunohistochemistry on serial sections for EGFR was 
evaluated (Fig. 37B). Positive nuclear and membranous EGFR staining in control tumors 
(left) were observed, whereas in dasatinib-treated tumors (right), an increase in diffused 
membranous EGFR staining was observed (Fig. 37B, top). Examination of pSrc (Y416) 
expression (Fig. 37B, bottom) showed a decrease in total staining between control, 




untreated tumors (left) and dasatinib treated tumor sections (right). 
 To assess the treatment response to combination dasatinib and cetuximab 
therapy, the mice were treated with the combination for three additional weeks and tumor 
volumes were measured (Fig. 37C). There was a significant (p = 0.0006) improvement in 
response to treatment in the combination mice compared to untreated control. Untreated 
mice had an average tumor volume of 85.18 ± 26.71 mm3, compared to combination 
treated mice with an average tumor volume of 3.53 ± 7.07 mm3, with 3 out of the 4 tumors 
completely regressing in volume. Change in tumor volume expressed as a percentage of 
starting tumor volume was correlated to 89Zr-cetuximab tumor uptake (%ID/g) (Fig. 37D). 
There was a significant, negative correlation between tumor regression and VOI (r = -






Figure 37. Ex vivo tumor TM00089 tumor analysis and extended combination 
treatment. Ex vivo autoradiography (A), H&E (B, bottom), and IHC of EGFR (B, top) and 
pSrc (Y416, B, middle) shows differences in tracer localization and expression after 
dasatinib treatment (right) compared to control (left). Correlation between 89Zr-cetuximab 
tumor VOI (%ID/g) and percent change in tumor volume after treatment regimen in 




Recently, 89Zr-labelled antibodies nimotuzumab(245), imgatuzumab(246), and 
panitumumab(36,247), and affibody ZEGFR:2377(22) have been under investigation for 
use in imaging EGFR expression in vivo in addition to 89Zr-cetuximab(248). Throughout 
these studies, EGFR has been established as a promising and robust target for 
A.  B.  




immunoPET imaging and targeted radiotherapeutics(249). Unfortunately, disparities 
between in vivo EGFR expression and 89Zr-cetuximab PET uptake have been 
observed(248).  This may be in part, due to the compartmentalization of EGFR between 
the nucleus and plasma membrane(168). The non-receptor tyrosine kinase Src has 
shown to be a key modulator of nEGFR translocation(239), and is an important 
downstream node of cetuximab response pathways(166,168,240,250). The literature and 
these studies have shown that targeting Src with dasatinib in TNBC cell lines expressing 
high levels of nEGFR in vitro resulted in a translocation of EGFR to the plasma 
membrane, suggesting this pathway a strategy to enhance EGFR available for further 
anti-EGFR treatments(251). Additionally, patients with high nEGFR expression have poor 
survival and prognosis in non-small cell lung cancer(237). 
The Window of Opportunity Trial of dasatinib in operable triple negative BCs with 
nEGFR (NCT02720185) is currently underway to determine if dasatinib can prevent 
nuclear translocation of EGFR in stage I-III TNBC. Patients will be subjected to oral 
dasatinib (100 mg) treatment 7-10 days prior to planned surgery or research biopsy and 
plasma membrane EGFR expression will be measured. An increase of at least 25% 
membrane EGFR expression from baseline to post-dasatinib treatment will be considered 
significant. With this perspective, the initiative to validate 89Zr-cetuximab as a tool to non-
invasively monitor the translocation of nEGFR to the membrane is potentially useful for 
selection patients who’ve responded to dasatinib and could further benefit from EGFR 
targeted therapies.  
Specifically, these results have shown that 89Zr-cetuximab detects higher plasma 




dasatinib treatment, as shown by binding and internalization assays. The lower 
internalization was coupled with an increase in total EGFR levels and a decrease in 
pSrc(Y416) levels, which confers Src response to dasatinib, as measured by western 
blots. In vivo studies demonstrated 89Zr-cetuximab uptake increased after dasatinib 
treatment in TNBC xenografts MDA-MB-231 and MDA-MB-468. This was validated 
through ex vivo autoradiography, histology, and western blots. Immunohistochemistry 
looking at EGFR localization demonstrated an increase in membranous EGFR after 
dasatinib treatment in all xenografts, coupled with a decrease in pSrc(Y416) expression. 
Western blots of tumor lysates have shown an increase in total EGFR levels, with a 
concomitant decrease in pEGFR(Y845) and pSrc (Y416) levels, conferring response to 
dasatinib. Further analysis into utilizing this read out as a predictive biomarker of 
cetuximab response was evaluated in KRAS mutant cells MDA-MB-231, and KRAS wt 
cells MDA-MB-468. Tumor VOI significantly correlated with tumor response to treatment 
in MDA-MB-468 cells, and was coupled with a significant treatment benefit, whereas in 
MDA-MB-231 cells, there was no benefit to cetuximab observed. Taken collectively, 89Zr-
cetuximab PET imaging can potentially be utilized in clinical trials to measure EGFR 
translocation from the nucleus to the membrane in patients treated with dasatinib, and 





CHAPTER 4. UTILIZING IMMUNOPET IMAGING TO MONITOR TUMOR RESPONSE 
TO IMMUNOTHERAPY 
 
This chapter was adapted in full from “Interferon-gamma PET imaging as a 
predictive tool for monitoring response to tumor immunotherapy” by Heather Gibson, 
Brooke McKnight, Agnes Malysa, Greg Dyson, Wendy Wiesend, Claire McCarthy, Joyce 
Reyes, Wei-Zen Wei, and Nerissa T. Viola-Villegas originally published in Cancer 
Research and used with their full permission. 
4.1 INTRODUCTION 
During adaptive immunotherapy, activated T cells infiltrating a tumor are often the 
principal components of treatment providing a “search-and-destroy” mechanism through 
specific recognition of tumor-associated antigens (TAA)(252,253). Recent emerging 
tumor-targeted ITx strategies are met with positive and durable outcomes in a subset of 
patients, however many remain non-responsive, exposing a strong urgency for consistent 
methods to monitor therapeutic response in a timely manner(203). Peripheral immune 
monitoring assays are often restricted to one antigen, are non-standardized, and may not 
reflect the dynamic activity occurring within the tumor(254,255). Post-treatment biopsy 
can be used to evaluate tumor infiltrates(256) however tumor heterogeneity and general 
accessibility may impact the adequacy and/or feasibility of this approach(257). Image-
guided focal analysis of intratumoral immune activity may eliminate these issues by 
providing non-invasive, real-time efficacy predictions in situ. To date, ITx positron 
emission tomography (PET) tracer development has focused on immune cell surface 
molecule detection, particularly against CD3(47), and CD8(258). Others have developed 
tracers targeting immune checkpoint molecules PD1/PD-L1(42,43,259–262) to help 




however, as they do not mark functional downstream effector tumoricidal activity. 
The cytokine interferon-γ (IFN-γ) is predominantly produced by activated Type 1 T 
helper (Th1)-skewed CD4 T cells, cytotoxic CD8 T cells (CTL), and both NK and NKT 
cells(263). Both Th1 and CTL contribute to antigen-specific tumor cell recognition and 
destruction, which is particularly advantageous in the context of immunotherapeutic 
approaches including checkpoint blockade, adoptive cell therapies, and vaccination(264–
266). IFN-γ signaling contributes to tumor cell killing by a variety of mechanisms including 
upregulation of Fas/FasL and MHC molecules (267,268), however tumor expression of 
PD-L1 is also positively regulated by IFN-γ signaling, which ultimately serves as a 
feedback mechanism to quell immune activation.   
 The focus of this study described in this chapter underscores the development of 
a monoclonal antibody PET tracer targeting IFN-γ. The results show that IFN-γ PET 
associates with response to immunotherapy. Tumors treated with TAA DNA vaccination 
show increased IFN-γ detection with an influx of T cells. The level of IFN-γ uptake 
inversely correlates to tumor growth rate. Alternatively, in a model of induced T cell 
exhaustion, T cells were found to infiltrate the tumor but failed to produce detectable IFN-
γ as measured by PET imaging. Results further demonstrated that IFN-γ PET provides 
consistent sensitivity for the detection of immunotherapy response when compared to 
antigen-specific peripheral immune monitoring. Collectively, IFN-γ PET may serve as a 
non-invasive, comprehensive approach to the evaluation of tumor immunotherapy. 
4.2 RESULTS 
4.2.1 PET imaging to visualize Neu+ tumors and CD3+ T cell infiltration 




were visualized by imaging tumor bearing mice with an anti-neu probe, 64Cu-Ab4. 64Cu 
was selected as the tracer due to its short half-life (t1/2 ~ 12.07 h) and its applicability 
towards serial imaging studies. NeuT mice (n = 4) with palpable tumors exhibited a tumor 
uptake of 5.43 ± 0.72 %ID/g at 4 h p.i., and increased to 7.15 ± 0.45 %ID/g at 24 h p.i. (p 
= 0.5163)(Fig. 38A). Time-course imaging displayed a significant decrease in liver (17.0 
± 2.2 %ID/g to 9.5 ± 2.38 %ID/g, p < 0.0001) and heart (15.5 ± 2.3 %ID/g to 6.7 ± 1.8 
%ID/g, p < 0.0001) uptake from 4 h to 24 h, respectively (Fig. 38B). Tumor volumes as 
measured in mm3 were significantly correlated to tumor uptake at 24 h p.i. (r =0.832, p = 
0.002)(Fig. 38C).  
 
Figure 38. Visualizing presence of Neu+ tumors with 64Cu-Ab4. NeuT mice bearing 
palpable tumors (left) or no tumor (right) were imaged with 64Cu-Ab4 4 h or 24 h p.i. (A); 
time course imaging uptake of tumor, liver, heart, and muscle (B); NeuT tumor volumes 





 CD3+ T-cell infiltrates were next visualized within the tumor microenvironment with 
an anti-CD3 tracer, 89Zr-anti-CD3. Tumor bearing NeuT mice were injected with 89Zr-anti-
CD3 and serially imaged from 4 h to 72 h p.i. (Fig. 39). Tumor uptake did not significantly 
change over time, with 3.4 ± 0.5 %ID/g at 4 h p.i., and decreasing to 3.1 ± 0.6 %ID/g at 
72 h p.i. (p = 0.960). Heart uptake increased from 5.35 ± 2.8 %ID/g to 6.23 ± 3.83 %ID/g 
after 72 h p.i. (p = 0.607). Liver uptake significantly increased after 72 h, from 8.28 ± 2.02 
%ID/g to 10.78 ± 1.36 %ID/g (p = 0.005). Spleen uptake significantly increased after just 
48 h, from 10.08 ± 0.9 %ID/g to 16.58 ± 1.65 %ID/g (p < 0.0001), and continued to rise 
after 72 h to 18.53 ± 3.0 %ID/g (p < 0.0001). 
Figure 39. Time course imaging of 89Zr-anti-CD3. Mice were injected with 
89
Zr-anti-
CD3 and images of MIP are shown for each time point (top). L = liver, S = spleen. A plot 





4.2.2 89Zr-anti-IFN-γ PET tracer identifies localized IFN-γ production 
The rat mAb AN-18 to murine IFN-γ was labeled with 89Zr using desferrioxamine 
as the chelate (89Zr-anti-IFN-γ) in good yields and purities according to previously 
reported methods(269). Timecourse imaging was performed on mice bearing tumors at 
24, 72, and 120 h p.i. (Fig. 41). At 24 h, there was 12.0 ± 3.2% ID/g within the tumor. At 
72 h p.i., there was 11.7 ± 3.1 %ID/g within the tumor, and plateaued at 12.7 ± 3.0 %ID/g 
after 120 h p.i. Time activity curves demonstrate a consistently low muscle uptake. At 72 
h p.i., heart uptake decreases to below tumor uptake levels, and is the time where we 
determined subsequent imaging experiments would take place. Spleen uptake, a 
secondary lymphoid organ, was consistent throughout all timepoints. 
Figure 40. Time course imaging of 89Zr-anti-IFNγ.  Mice were injected with 89Zr-anti-
IFNγ and images of MIP are shown for each time point (top). H = heart, T = tumor. A plot 
of the volumes-of-interest obtained from select tissues is shown over time from 24-120 h 
p.i. 
 
In mice treated with CpG-ODN to stimulate IFN-γ, whole-body PET images were 




low liver and blood pool background (Fig. 41A). VOIs drawn on splenic tissues 
demonstrated higher tracer accumulation (3.50 ± 0.61 %ID/g, n=3) in CpG-ODN-treated 
groups compared to untreated controls (Ctrl: 0.83 ± 0.12 %ID/g, n=3) (Fig. 38B). 
Tissue distribution of 89Zr-anti-IFN-γ at 72 h p.i. demonstrated 20.04 ± 12.2 %ID/g 
uptake in the spleen (Fig. 41B, Table 14). Uptake within the blood circulation (0.67 ± 0.69 
%ID/g), as well as tissues responsible for excretion, liver (9.77 ± 9.12 %ID/g), and kidneys 
(3.93 ± 0.6 %ID/g) were low. There was also low uptake in the bone and muscle. 
Specificity was further confirmed through competitive binding experiment where a 
decrease in spleen uptake (20.04 ± 12.20 vs. 1.88 ± 2.74 %ID/g, n=4, p=0.0061) with 10X 
cold mAb blockade was observed, consequently increasing non-specific tissue 
accumulation in the blood (19.46 ± 12.69 %ID/g, p=0.0043), heart (10.57 ± 8.91, p=0.30), 
and liver (11.69 ± 9.82 %ID/g, p=0.99). Notable differences in splenic uptake in the 
imaging and tissue distribution (10-fold lower mass) are due to “mass effects”, wherein a 
greater mass of protein administered potentially saturated receptor binding sites and 
rendered slower pharmacokinetics(57). 
Since IFN-γ is a soluble protein, the mechanism of localized IFN-γ imaging was 
investigated. Plated TUBO tumor cells were exposed to IFN-γ and/or 89Zr-anti-IFN-γ tracer 
in quintuplicate followed by analysis of membrane binding and internalization (Fig. 41C). 
TUBO cells incubated with 89Zr-anti-IFN-γ alone show limited tracer surface binding (1.13 
± 0.28%) and internalization (0.29 ± 0.13%). When TUBO is pre-incubated with IFN-γ, 
enhanced 89Zr-anti-IFN-γ surface binding (13.62 ± 2.60%) and internalization (3.93 ± 
1.07%) is observed (membrane: p=0.00039, internalized: p=0.0015). Detection of tracer 




sequestration of IFN-γ on its receptor in vivo. 
Figure 41. Validation of specificity of 89Zr-anti-IFN-γ A) BALB/c mice treated with CpG-
ODN and imaged with the tracer 72 h p.i. displayed higher uptake in the spleen compared 
to control (Ctrl) untreated cohorts (n=3 each). B) Tissue distribution of 
89
Zr-anti-IFN-γ at 
72 h p.i. demonstrated lower probe accumulation in the spleen upon competitive 
saturation with 10× cold AN-18 mAb (n=4 each). C) Binding of 
89
Zr-anti-IFN-γ receptor-
localized IFN-γ was tested in vitro. TUBO cells were incubated with 
89
Zr-anti-IFN-γ alone 
(n=5), or with recombinant IFN-γ (rIFN-γ) and washed before addition of 
89
Zr-anti-IFN-γ 
(n=5). Activity was measured by a gamma counter and adjusted for cell count. * denotes 







Table 14. Biodistribution with 89Zr-anti-IFNγ   
4.2.3 IFN-γ PET detects active anti-tumor immunity in situ in a syngeneic tumor 
model 
To test the capacity of 89Zr-anti-IFN-γ as a non-invasive measure of anti-tumor 
immune response, neu+ TUBO tumor bearing BALB/c mice were imaged after receiving 
two rounds of HER2/neu DNA vaccination as detailed in Figure 42A. This vaccine induces 
HER2-specific humoral and T cell responses and ~10% equivalent of cross-reactive anti-
neu T cells without cross-reactive neu-specific antibody(270). Tumor volumes began to 
stabilize or regress within 1 week after the second vaccination compared to untreated 
TUBO-bearing mice (Fig. 42A). Mice were injected with 89Zr-anti-IFN-γ tracer for PET 
imaging (Fig. 42B and Fig. 43) at 72 h p.i. A nearly two-fold increase in tumor uptake was 
Tissue Control 10× mAb block 
 
 
Mean ± S.D. Mean ± S.D. p-value 
Spleen 20.04  ± 12.20 1.88 ± 2.74 0.0061 
Blood 0.67  ± 0.69 19.46 ± 12.69 0.0043 
Heart 0.30   ± 0.04 10.57 ± 8.91 0.2956 
Liver 9.77  ± 9.12 11.69 ± 9.82 0.9999 
Kidneys 3.93 ± 0.60 10.64 ± 7.18 0.7755 
Bone 4.19 ± 1.18 1.01 ± 0.94 0.9951 




observed in vaccinated (Vx: 10.07 ± 1.50 %ID/g, n=6) versus control mice (Ctrl: 5.97 ± 
0.61 %ID/g, n=6, p=0.0001). An 89Zr-labeled rat IgG isotype control tracer demonstrated 
similar tumor accumulation (72 h p.i.) in both untreated (5.27 ± 0.79 %ID/g) and 
vaccinated (5.93 ± 0.85 %ID/g) mice. This suggests baseline intratumoral IFN-γ levels are 
low without treatment. The notable low accumulation of the isotype control tracer after 
vaccination supports the specificity of the IFN-γ tracer and suggests increased 89Zr-anti-

























Figure 42. PET evaluation of immunotherapy response in orthotopic TUBO 
mammary tumors. Tumor volume was monitored in both untreated control (Ctrl, n=11, 
left) and vaccinated (Vx, n=12, right) tumors. TUBO cells were inoculated 10 days prior 
to the start of vaccinations, given on days 0 and 14. PET imaging was conducted on day 
15 (Ctrl) and 21 (Vx) (A); Representative whole body maximum intensity projections (MIP, 
top row) and planar (bottom row) images of control (left panels, n=6) and vaccinated (right 
panels, n=6) mice with 
89
Zr-anti-IFN-γ tracer (left). White circle = tumor, L = liver, H = 
heart, S = spleen, Th = Thymus. Tumor VOIs were measured for each mouse with an 
89
Zr 
labeled rat IgG isotype control included for each treatment group (n=3, untreated control; 
n=6, vaccinated control) (B); MIP image (top panels) and planar sections (bottom panels) 
of 
89
Zr-anti-CD3 images in control (left, n=5) and vaccinated mice (middle, n=6) (C). A 
non-specific 
89
Zr labeled Armenian hamster IgG isotype control was used to measure 




Figure 43. MIP images of 89Zr-anti-IFNγ. Detection in all control (left) and vaccinated 
(right) TUBO bearing mice. 
4.2.4 Detection of tumor infiltrating lymphocytes via CD3 immunoPET 
Total T cell presence in the tumor microenvironment was assessed in separate 
groups of mice via immunoPET imaging of CD3+ tumor infiltrating lymphocytes using 
89Zr-anti-CD3 (Fig. 42C and Fig. 44). Vaccinated tumors exhibited a modest, insignificant 
increase of CD3 tracer binding compared to control (6.25 ± 0.37 %ID/g, n=6 vs. 4.58 ± 
0.83 %ID/g, n=5, p=0.16). Both cohorts failed to demonstrate a significant change in 
uptake compared to Armenian hamster isotype control IgG (5.90 ± 1.26 %ID/g, n=3, 
p=0.87 (Ctrl), p=0.49 (Vx)). Untreated TUBO tumors have endogenous T cell infiltrates 




suboptimally detected these TILs in both untreated and vaccinated mice with measured 
VOIs similar to the non-specific IgG tumor accumulation. This may be due to excessive 
uptake by the spleen, a T cell-homing secondary lymphoid tissue (Ctrl: 17.06 ± 3.56 
%ID/g, Vx: 18.36 ± 1.49 %ID/g, Fig. 45B), which can act as a tracer “sink.” In contrast, 
limited splenic accumulation was observed with the IFN-γ PET probe (Ctrl: 3.58 ± 0.81 




Figure 44. MIP images of 89Zr-anti-CD3. Detection in all control (left) and vaccinated 





Figure 45. T cell detection in TUBO-bearing BALB/c. Tumors from untreated TUBO-
bearing mice were dissociated and stained with CD45, to detect total leukocyte infiltrates, 
and the T cell receptor beta chain (TCRβ), to identify the T cell fraction, by flow cytometry 







4.2.5 Ex vivo validation via IHC, qPCR, and ELISA 
Upon completion of imaging, tissues were collected for ex vivo validation. Tumor 
tissue was assessed to verify CD3+ and CD8+ T cell presence, as well as expression of 
IFN-γ. Transcripts levels of CD3, CD8 and IFN-γ were increased in tumor tissue after 
vaccination (Fig. 46A, Ctrl: n=11, Vx: n=13), in concordance with the PET imaging data. 
Cultured TUBO cell cDNA is included as a negative control. CD3 and CD8 proteins were 
increased after treatment (46B) and intratumoral IFN-γ protein was also confirmed and 
quantitated by ELISA (Fig. 46C). ELISA results showed higher total IFN-γ in Vx (n=11) 
versus Ctrl (n=10) TUBO tumors (85.37 ± 65.89 vs. 41.69 ± 20.12 pg/mg tissue, p=0.043).  
Peripheral vaccine-induced immunity was measured by HER2/neu-specific serum 
IgG (Fig. 46D) and splenic T cell responses (Fig. 46E). HER2-specific IgG was only 
detected in vaccinated mice (18.68 ± 7.40 µg/mL, n=14, p<0.0001). TUBO tumors 
constitutively express the cell surface oncogene neu, which is foreign in wild-type BALB/c 




1.60 µg/mL, n=13), which is further increased in vaccinated animals (6.18 ± 7.34 µg/mL, 
n=14, p=0.0019). While the HER2 DNA vaccine itself does not induce anti-neu IgG(270), 
tumor cell killing likely enhances immune activity to this foreign antigen. Detection of 
HER2-specific IFN-γ-producing T cells was restricted to vaccinated mice, similar to anti-
HER2 IgG (119.40 ± 95.18/106 splenocytes (SC), n=7, vs. 0.83 ± 2.04/106 SC in untreated 
controls, n=6, p=0.0012). Peripheral anti-neu T cells were detected in all vaccinated 
animals (8.33 ± 7.75/106 SC) while only 1 of 4 untreated controls showed T cell 
responsiveness to neu (0.83 ± 2.04/106 SC, p=0.033). The absolute quantities of HER2 
and neu-specific IgG and T cells were ~10-fold lower than similarly vaccinated non-tumor-
bearing mice(270). This may be due to tumor-associated immune suppression by 
myeloid-derived suppressor cells or regulatory T cells (Tregs), which are reportedly 
























Figure 46. Ex Vivo validation of immunotherapy response in TUBO-bearing mice. 
Tumors were removed after imaging and validated. A) Total RNA obtained from Ctrl (n=11) 
and Vx (n=13) tumor tissue was analyzed by qPCR with primers specific to CD3 (left), 
CD8 (middle), and IFN-γ (right). Cultured TUBO cells serve as control (n=2). B) Western 
blots from lysed decayed tumor tissues post-CD3 or IFN-γ PET were conducted to 
analyze presence of CD3 and CD8 protein in the Vx vs Ctrl mice. C) IFN-γ ELISA was 
conducted with protein lysates of TUBO tumor segments of control Ctrl (n=10) and Vx 
(n=11) mice. D) HER2 and neu-specific IgG were measured in serum by flow cytometry 
(Ctrl: n=13, Vx: n=14). E) HER2 and neu-responsive T cells were measured by IFN-γ 






4.2.6 Detection of ITx response in a spontaneous tumor model 
 The capacity of IFN-γ PET imaging to detect anti-tumor immune activity was tested 
in a spontaneous tumor setting. Neu transgenic (NeuT) mice are engineered to express 
a transforming rat neu under the mouse mammary tumor virus promoter(273), allowing 
immune system recognition of neu as a self-antigen(270). Studies were conducted in 
male NeuT mice, which develop 1-2 spontaneous neu+ salivary tumors between 30-40 
weeks of age(273). Once tumors were palpable, Tregs were depleted using anti-CD25 
mAb clone PC61 to enhance ITx response given NeuT mice are immune tolerant to rat 
neu(270,274), followed by two HER2/neu DNA vaccinations. Vaccination of NeuT mice 
(n=7) controlled tumor growth rate compared to untreated (n=6) tumor-bearing NeuT mice 
(Fig. 47A, p=0.032). IFN-γ PET of vaccinated tumors displayed a nearly two-fold higher 
uptake of 89Zr-anti-IFN-γ (8.37 ± 0.35 %ID/g, n=4) vs. control (4.63 ± 0.47 %ID/g, n=3, 
p=0.001), indicating infiltration of functional anti-tumor T cells (Fig. 47B and Fig. 48B). An 
examination of tumor infiltrates via CD3 PET (Fig. 47C and Fig. 48B) revealed a similar 






















































Figure 47. PET detection of anti-tumor immunity in spontaneous tumor-bearing 
NeuT mice. Control, untreated mice (Ctrl, n=6) were imaged by PET after palpable 
tumors were permitted to grow 31 days. For vaccinated mice (Vx, n=7), upon detection of 
palpable spontaneous salivary tumors, regulatory T cells (Treg) were depleted 10 d prior 
to the first vaccination. Mice received two HER2/neu DNA vaccinations 14 d apart. PET 
imaging was conducted 7 days after the final vaccination (A); representative whole body 
maximum intensity projections (MIP, top row) and planar (bottom row) images of control 
(left panels, n=3) and HER2/neu DNA-vaccinated (right panels, n=4) mice with 
89
Zr-anti-
IFN-γ tracer (left) (B). White circle = tumor, L = liver, S = spleen. Tumor VOIs were 
calculated for each mouse. C) Representative CD3 PET images of MIP (top) and planar 

























Figure 48. 89Zr-anti-IFNγ and 89Zr-anti-CD3 PET in all tumor-bearing NeuT mice. MIP 
images of (A) 
89
Zr-anti-IFNγ and (B) 
89
Zr-anti-CD3 detection in all control (left) and 
vaccinated (right) NeuT mice bearing spontaneous salivary tumors. Tumors are indicated 
by arrow; L = liver. 
Validation of T cell infiltration and IFN-γ production was conducted by qPCR in 






insignificant increase after vaccination, while IFN-γ mRNA increased (Ctrl: n=3, Vx: n=5, 
p=0.036). Peripheral immune response to the vaccine was evaluated by measuring 
serum anti-HER2 and anti-neu IgG as well as spleen-resident HER2- and neu-responsive 
IFN-γ-producing T cells. Tolerance to HER2/neu in NeuT mice was apparent with a 
comparatively lower ITx response vs. wild-type BALB/c mice bearing TUBO tumors in 
Figure 2. HER2-specific IgG was detected in vaccinated animals (Fig. 49B, 8.7 ± 4.9 
µg/mL, n=8, p=0.0016 vs. Ctrl, n=5), while anti-neu IgG was negligible or absent in all 
samples tested. Despite increased intratumoral detection of IFN-γ in vaccinated NeuT 
mice by PET, peripheral T cell response to neu was low (Fig. 49C, 15.80 ± 8.84/106 SC, 
n=5) with HER2 vaccination, and was not significantly increased relative to untreated 
control (n=5, p=0.27). that detected in non-immune tolerant BALB/c mice bearing TUBO 
(10.0%, Fig. 49C). These results support the hypothesis that peripheral immune 
monitoring may be an inadequate measure of anti-tumor immunity with tumor-responsive 
T cells preferentially localizing within the tumor, supporting the use of in situ analysis 

























Figure 49. Ex vivo validation of anti-tumor immunity in spontaneous tumor-bearing 
NeuT mice. A) Total RNA was isolated from tumor tissue and qPCR analysis for CD3, 
CD8, and IFN-γ was conducted (n=3 each) B) Serum HER2 (Ctrl, n=5; Vx, n=8) and neu-
specific IgG (Ctrl, n=5; Vx n=8) was measured by flow cytometry. C) HER2 and neu-
responsive T cells were measured by IFN-γ ELISPOT (n=5 each). * denotes p < 0.05, ** 




4.2.7 IFN-γ PET imaging is an indicator of immune activation status in situ 
To test the capacity of 89Zr-anti-IFN-γ to predict treatment outcomes, BALB/c mice 
(n=11) bearing variably-sized TUBO tumors were treated with our HER2 vaccine as 
described previously, resulting in a range of growth slopes (Fig. 50A, Fig. 51). 89Zr-anti-
IFN-γ PET imaging was conducted two weeks after the final vaccination and tumor volume 
was monitored for an additional ten days. Tumor-localized 89Zr-anti-IFN-γ tracer uptake 
inversely correlated with tumor growth rate (Fig. 50B and Fig. 4.13, r=-0.64, 95% CI: (-
0.90,-0.06); p=0.034), suggesting IFN-γ PET is an indicator of the effects of ITx on these 
tumors.  
The outcome of IFN-γ PET in a setting where tumor-infiltrating T cells are present 
but have become exhausted was evaluated. TUBO-bearing mice were treated with 
passive ITx, mAb 7.16.4 to rat neu. This mAb has been shown to inhibit neu signaling in 
addition to initiating host anti-tumor immunity(275,276). Once tumors were established at 
~50 mm3, 1 mg doses of 7.16.4 were given i.p. at 3-4 day intervals for a total of 5 
treatments, which reduced and stabilized tumor growth (Fig. 50C). 89Zr-anti-IFN-γ (n=5) 
or control IgG (n=6) PET imaging was conducted on day 30 after treatment onset, at 
which time tumor growth had resumed. Tumor uptake of IFN-γ tracer was 
indistinguishable from IgG control, suggesting a lack of immune activity (Fig. 50D). CD8 
T cell infiltration was evaluated by IHC (Fig. 50E). Blinded pathologist enumeration of the 
three regions with highest infiltration was calculated, showing a 12-fold increase in CD8 
T cells after 7.16.4 treatment versus control (Ctrl: 3 ± 1, 7.16.4: 36 ± 19). Vaccinated 
TUBO tumor had the largest detected CD8 infiltration (74 ± 25). Overall, CD8+ tumor 




detectable CD8+ TILs (Fig. 50E). We further validated CD8 T cell infiltration after 7.16.4 
therapy by flow cytometry in a parallel cohort of treated and control mice (Fig. 50F, n=4 
each). An overall increase in CD45+ infiltrates (Ctrl: 6.84 ± 1.85%, 7.16.4: 16.95 ± 5.88%, 
p=0.036) and CD8+ T cells (Ctrl: 0.41 ± 0.19%, 7.16.4: 4.96 ± 1.96%, p=0.018) was 
detected after mAb treatment. Interestingly, the majority of CD8+ TILs expressed the T 
cell exhaustion marker PD-1 (Fig. 50G, 79.7 ± 10.3%) compared to control tumors (20.5 
± 9.3%, p=0.0001). Collectively these results suggest this treatment model promotes an 
inactive and exhausted CD8 T cell status despite tumor infiltration, leading to reduced 


























Figure 50. IFN-γ PET depicts response to ITx. Tumor volume was monitored in TUBO-
bearing vaccinated BALB/c mice (n=11). TUBO cells were inoculated 13 days prior to the 
start of vaccinations, to allow for variability in tumor volumes at treatment onset. Vaccines 
were given on days 0 and 14. PET imaging was conducted on day 28 (A); weekly tumor 
growth rate, calculated by regression analysis of log tumor growth, versus 
89
Zr-anti-IFN-
γ tracer uptake is plotted for each mouse and evaluated by Pearson’s correlation (B); 
tumor growth was monitored during passive immunotherapy with anti-neu mAb 7.16.4, 
given as 5 doses at 1.5 mg i.p. every 3-4 days as indicated beginning 15 days after tumor 
inoculation. 
89
Zr-anti-IFN-γ (n=5) or 
89
Zr-rat-IgG control (n=6) PET imaging was 





Zr-rat-IgG tracers in 7.16.4 treated TUBO-bearing mice (D); intratumoral 
localization of CD8 was analyzed by IHC on FFPE tissue (400×). H&E sections are 
included. CD8 enumeration is found in the lower right corner of each panel (E); control 
and 7.16.4-treated tumors (n=4 each) were dissociated and analyzed for T cell infiltration 
by flow cytometry by staining for CD45 and CD8 (F); PD-1 expression was analyzed by 



















































































































Several major drawbacks to the use of general T cell surface markers and immune 
checkpoint ligands for PET imaging can complicate the assessment of immunotherapy 
response. T cells are densely present in normal secondary lymphoid tissues, such as the 
spleen, thymus and lymph nodes, which may hinder tumor-specific T cell imaging. 
Intratumoral detection of total CD3+ T cells and CD8+ cytotoxic lymphocytes has been 
shown to positively correlate with patient outcomes(277,278). However, the chronic 
inflammatory tumor microenvironment promotes checkpoint molecule expression, driving 
cytotoxic T cells into an exhausted state with diminished effector activity. Visualizing 
components of checkpoint signaling axes (e.g. PD1/PD-L1) can provide go-or-no-go 
treatment decisions by selecting patients with higher likelihood of responding to 
checkpoint blockade(279). In general, these methods do not measure downstream 
effector function of cytotoxic T cells. Larimer et al. reported on the utility of a peptide-
based imaging tracer specific granzyme B, a cytotoxin released by activated CTL using 
a syngeneic colon cancer model(45). The tracer identified responders from non-
responders after mono- or combinatorial anti-CTLA-4 and anti-PD1 targeted inhibition; 
however, it is unclear whether the peptide tracer (7.46 ± 2.24 µg per mouse) solicited 
inhibitory effects on the enzymatic activity of granzyme B. Nevertheless, the study 
substantiates the rationale that imaging effector molecules along the T cell signaling axis 
may provide a better readout of immune response to treatment.  
In this study, the capabilities of IFN-γ PET were demonstrated to measure active 
anti-tumor immunity, providing a predictive tool for non-invasive in situ tumor evaluation. 




fact that IFN-γ is secreted by CTLs within the tumor. Imaging CD3, on the other hand, 
targets the general T cell population that are not only localized in the tumor but also in 
other lymphoid tissues. Find antibody-based tracers to immune cell surface molecules 
were found to may create artifacts in the experimental system. Efforts to label CD8-
specific full-length mAbs (clones 2.43 and non-depleting YTS-105.18) resulted in 
depletion of the target cell population and tracer accumulation in the kidneys with lack of 
secondary lymphoid tissue detection (data not shown) despite detection of CD8+ tumor 
infiltrates by flow cytometry and IHC (Fig. 6E-F). Anti-CD3 mAb clone 2C11 is routinely 
utilized for its pan-T cell receptor agonist activity, which may also potentially alter T cell 
function in vivo. Alternatively, it is conceivable that tracers to surface receptors may 
antagonize signaling, which could create off-target effects. Careful selection of antibody 
clones or construction of antibody fragment-based tracers like the CD8 diabody 
generated by Tavare et al.(213) or the VHH probe by Rashidian et al.(258) may alleviate 
some of these factors, but thorough quality control is necessary. Tracers targeting soluble 
cell products may also circumvent many of these problems. 
A caveat to detection of cytokines by PET imaging is the soluble nature of these 
proteins. Localization of 89Zr-anti-IFN-γ was observed in the spleen after CpG-ODN 
treatment and in the tumor after HER2/neu vaccination, suggesting the tracer is 
sequestered within the tissue.89Zr-anti-IFN-γ complexes in vitro and find maximal binding 
when TUBO cells are pre-incubated with IFN-γ, supporting the working hypothesis that 
localized imaging is due to detection of IFN-γ associated with its receptor. 
Ex vivo validation experiments showed a general trend in agreement with the PET 




similar to a biopsy, are sampling a fragment of a heterogeneous tumor, yielding 
opportunity for equivocal results. Further, our IHC analyses on TUBO tumors (Fig. 6E) 
show the tissue is non-uniform, with regions of variable CD8 T cell infiltration after ITx 
ranging from moderate density to a virtual absence. For these reasons, imaging tools like 
immunoPET are advantageous, bridging a clinical need by providing a more 
comprehensive view of the entire tumor microenvironment.  
These results showed 89Zr-anti-IFN-γ tracer uptake can be indicative of response 
to therapy in both cancer vaccination and TAA-specific mAb models. IFN-γ PET further 
demonstrated it may be more sensitive for determining response to immunotherapy when 
compared to peripheral immune evaluation, a point which should be evaluated further. 
IFN-γ PET has the potential to serve as a universal non-invasive measurement of immune 
activity in situ for a variety of cancers with virtually any immunotherapy modality with no 
need for knowledge of specific antigens or cumbersome ex vivo antigen recall assays. 
Additionally, the utility of IFN-γ PET can potentially expand beyond cancer immune 
monitoring to include examination of localized inflammatory conditions such as injury, 
infection, or autoimmune disease. Taken together, these results support the development 





CHAPTER 5. MATERIALS AND METHODS 
5.1 In vitro cell culture and in vitro tumor induction 
5.1.1 Cell culture and propagation 
All cells were adhered and grown at 37 °C with 5% CO2 according to the following 
conditions listed in Table 15.  All cells were split once they reached 80% confluence and 
were tested for mycoplasma with MycoAlert Mycoplasma Detection Kit (Lonza) and 
certified by the Biobanking and Correlative Services Core at Wayne State University. 
Cell Line Characteristic Media Passage  Obtained 
BT-474 ER+, HER2+ 
1:1 DMEM:F12 
(VWR) + 5% FBS + 












DMEM + 1% Pen-
































10% FBS, 1% L-
glutamine, 1% NEAA, 
















5.1.2 Tumor induction  
All animal handling and manipulations were conducted in accordance with the 
guidelines set by Wayne State University Institutional Animal Use and Care Committee. 
Female athymic nu/nu mice (6-8 week old) were purchased from Charles Rivers 
Laboratories (Wilmington, MA). All cells in 150 µL 1:1 media:Matrigel (BD Biosciences, 
Bedford, MA) were injected on the right shoulder at concentrations listed in Table 16. 
Monitoring of tumor growth was performed weekly with calipers. The tumor volume was 
calculated using the formula: length × width × height × pi/6. Mice with tumor volumes 
ranging from 150 – 250 mm3 were utilized. 
Cell Line Characteristic Xenograft Protocol (cells) 
BT-474 ER+, HER2+ 
Estrogen pellet 3 days prior 






MDA-MB-468 TNBC, EGFR-high 3×106 
MDA-MB-231 TNBC, EGFR-high 5×106 
MDA-MB-453 TNBC-EGFR low 5×106 
TM00089 TNBC, PDX - 
Table 16. Tumor inoculation protocol. 
5.1.3 NeuT mice and TUBO tumor induction 
Heterozygous BALB/NeuT (NeuT) mice were in-house bred and provided to us by 
the lab of Professor Wei-Zen Wei. NeuT male mice, which express a transforming rat neu, 
develop atypical ductal hyperplasia in 1-2 parotid glands by 6 weeks of age which 




BALB/c mice (6-8 week old) were purchased from Charles River Laboratories 
(Wilmington, MA) and were inoculated with TUBO cells in the #4 mammary fat pad. 
Monitoring of tumor growth was performed weekly with calipers. 
5.2 Antibody conjugation to chelates  
p-Benzyl-isothiocyanate-desferrioxamine (DFO-Bz-SCN, Macrocylics, Inc.) or  p-
SCN-Bn-1,4,7-triazacyclononane-1,4-7-triacetic acid (NOTA, Macrocyclics, Inc.) was 
conjugated to the antibodies listed on Table 17 according to previously published 
protocols(269). The synthesis was performed using the mole equivalence of DFO or 
NOTA to the antibody listed in Table 17 in 0.9% saline, pH ~9 at 37 °C for 1 h. The 
monoclonal antibody (mAb) DFO- or NOTA-conjugates were obtained by passing through 
a spin column filter with a molecular weight cut-off of 30 kDa (GE Vivaspin 500) using 
sterile saline as eluting buffer. 










Genentech 1:4 4  
Non-specific 
human IgG 
Sigma-Aldrich 1:4 5 14506 
Cetuximab 
(Erbitux®) 
Genentech 1:5 5  
Anti-CD3 eBioscience 1:5 5 145-2C11 









1:5 5 eBio299Arm 




Table 17. Antibodies and labeling conditions.  






Approximately 1 mCi (37 MBq) of 89Zr-oxalate (3D Imaging, LLC) was neutralized 
to pH 7.0 – 7.2 using 1 M Na2CO3. mAb-DFO (200 µg) was added to the 89Zr solution and 
pH was adjusted back to 7.0 if needed. The reaction was quenched after 1-1.5 h 
incubation at room temperature upon addition of 5 µL of 50 mM 
ethylenediaminetetraacetic acid (EDTA) (pH ~7.0) to eliminate any non-specifically bound 
radiometal. 
5.3.2 64Cu-radiochemistry 
mAb-NOTA (200 µg) was added to 1 mCi (37 MBq) 64Cu solution and the pH was 
adjusted to ~5 with 0.1 M ammonium acetate. The reaction was quenched after 1-1.5 h 
incubation at room temperature upon addition of 5 µL of 50 mM EDTA (pH ~7.0) to 
eliminate any non-specifically bound radiometal. 
5.3.3 Radiolabeling efficiency 
Radiolabeling efficiency was determined via radio-instant thin layer 
chromatography (iTLC) using silica gel-impregnated iTLC strip (Agilent Technologies, 
Santa Clara, CA) and 50 mM EDTA as the solid and mobile phase respectively. Pure 
89Zr-mAb or 64Cu-mAb was obtained through spin column centrifugation (GE Vivaspin 
500, MWCO: 30 kDa) with saline used for eluting unbound radiometal. mAbs were 




5.4 Drugs and Treatments 






Sellechem 75 mg/kg (Aim 1) 
50 mg/kg (Aim 2) 








CpG-ODN Integrated DNA 
Technologies 








In house 20 µg pGM-CSF + 
50 µg pE2TM 
See scheme 




7.16.4 In house 1 mg in filtered 
ascites 
5× 
every 3-4 d 
PBS 
i.p. injection 
Table 18. Drugs used in the studies. 
5.4.1 Molecular therapy 
Dasatinib was administered to tumor-bearing mice via oral gavage (p.o.) for 
treatment length described in Table 18. Untreated control mice were given a 1:1 mix of 
water and glycerol (150 µL total volume via oral gavage) as placebo. Cetuximab (i.p.) was 
administered intraperitoneally (i.p.) to tumor bearing mice (Table 18). Food and water was 
given ad libitum. Tumor volumes were recorded 2-3 times per week. Percent change in 
tumor volume was analyzed using measurements obtained before the start of treatment 
to the time of imaging following formula: ((start tumor volume – end tumor volume)/start 
tumor volume)×100.  
5.4.2 Immunotherapy 
For NeuT vaccination, mice were depleted of Tregs by intraperitoneal (i.p.) 
injection of 500 µg anti-CD25 mAb PC61 10 days prior to the first vaccination. The 
HER2/neu DNA vaccine consists of an admixture of 20 µg of pGM-CSF (encoding murine 




human HER2) in 50 µL PBS, which is injected intramuscularly (i.m.) into each 
gastrocnemius followed immediately by application of electrode gel and square wave 
electroporation using a BTX830 (BTX Harvard Apparatus, Holliston, MA). 
Mice bearing TUBO tumors were injected i.p. 5 times every 3-4 days with sterile-
filtered ascites containing 1 mg anti-neu mAb 7.16.4 diluted in PBS to a final volume of 
300 µL. 
5.5 IC50 Calculations 
Wells (96-well clear bottom plate, Corning) were seeded with ~1×104 cells and 
incubated for 18 h. Dasatinib was dissolved in DMSO (Sigma-Aldrich) at a 50 mM 
concentration. Serial dilutions of dasatinib (1nM to 1 mM) were made and cells were 
treated in 100 μL complete media and incubated for 72 h. Media was removed and cells 
were washed 1× with phosphate buffered saline (PBS) before addition of alamar blue 
(Life Technologies) in fresh media (1:10 Alamar blue:media) to measure cell viability. 
After 4 h incubation, absorbance was read at 570 nm on an Infinite M200 plate reader 
(Tecan). IC50 was calculated as the log(concentration) vs. absorbance – control well 
absorbance in GraphPad Prism (v. 7.02).5.5   
5.6 Internalization Assay 
Internalization of radiolabeled antibodies was evaluated on appropriate cell lines. 
Wells were seeded with ~5×105 cells and incubated for 18 h. Cells were treated with the 
established IC50 for dasatinib (Sellechem, reconstituted in DMSO) in complete media. 
After incubation, media was removed, and cells were washed 1 × PBS. Radiolabeled 
protein [1 µCi/mL (37 kBq/mL), 150 ng] in 1 mL of media was then added to each well. 




was collected, and the cells were rinsed with 1 mL 1× PBS, twice. Surface-bound activity 
was removed by washing the cells in 1 mL 100 mM acetic acid + 100 mM glycine (1:1, 
pH 3.5) at 4 °C. The cells were then lysed with 1 mL 1 M NaOH. All washes (media plus 
PBS, acid and alkaline) were collected in separate tubes and measured for bound activity 
using a gamma counter (Perkin Elmer). The %-internalized activity was calculated as the 
ratio of the activity of the lysate and the total activity collected from the media, PBS, acid 
and base washes, normalized to 50,000 cells counted using a Countess II Automated 
Cell Counter (Thermo Fisher). 
5.7 In vitro competitive binding assay 
Binding of radiolabeled mAbs was evaluated in appropriate cell lines. Wells were 
seeded with ~10×104 cells and incubated for 18 h. After incubation, radiolabeled protein 
[1 µCi/mL (37 kBq/mL, 100 ng)] in 1 mL of media was added to each well with or without 
10-fold excess unlabeled mAb (1 μg). The plates were incubated at 4 °C for 1 h. Following 
the incubation period, the media was collected and the cells were rinsed with 1 mL 1× 
phosphate buffered saline (PBS) twice. The cells were then lysed with 1 mL 1 M NaOH. 
All washes (media plus PBS and alkaline) were collected in separate tubes and measured 
for counts using a gamma counter (Perkin Elmer). The %-bound activity was calculated 
as the ratio of the activity of the lysate and the total activity collected from the media, PBS, 
acid and base washes, and was normalized to cell count using a Countess II Automated 
Cell Counter (Thermo Fisher). 
5.8 Western Blotting 
Cells were lysed on ice using 1× RIPA buffer (Pierce) supplemented with HALT 




using a handheld homogenizer Polytron PE 1200E (VWR) in the same buffer. Total 
protein was calculated by the Pierce BCA Protein Assay Kit (Thermo Fisher) using the 
microplate procedure and read at A562 nm.  
Lysates were prepared in NuPAGE lithium dodecyl sulfate (LDS) sample buffer 
(Life Technologies) supplemented with 2-mercaptoethanol (Sigma-Aldrich), and brought 
up to 15 µL with lysis buffer, and incubated at 95 °C for 5 min. Proteins (15 µg for cell 
lysates, and 10 µg for tumor lysates) and ladder (Precision Plus, BioRad) were separated 
on a 4-12% before transfer to Immobilon-P polyvinylidene difluoride (PVDF) membrane 
(Millipore Sigma. Membranes were blocked in 5% non-fat dry milk in tris-buffered saline 
(TBS) (KD Medical)-0.1% Tween20 (Amresco) for 1 h at room temperature. Primary 
antibodies were diluted 1:1000 in TBST with 0.02% sodium azide and incubated at 4 °C 
for 16 h with gentle rocking before blotting with horseradish peroxidase (HRP)-linked 
secondary antibodies in 5% milk-TBST for 2 h at room temperature (Table 19). Proteins 
were visualized using Amersham ECL (GE) and images collected using a ChemiDoc 
(BioRad) system. Images were analyzed using Image Lab (BioRad) software and 
densitometry was calculated using ImageJ software  






 Table 19. Antibody clones and catalog numbers used for western blotting. 
Anti-rabbit and anti-mouse HRP-linked secondary antibodies were purchased from 
GE (NA934, NA931). 
5.9 PET Imaging  
Injections were administered intravenously (i.v.) in the lateral tail vein in 100-150 
µL sterile saline (Table 20). Small-animal PET scans were acquired from 1-120 hours p.i. 
using a microPET R4 or Focus220 scanner (Siemens Concorde Microsystems). The mice 
were fully anesthetized with 1-2% isoflurane (Baxter, Deerfield, IL) during the scan. 
Images were reconstructed via filter back projection. ASIPro VMTM software (Concorde 
Microsystems) was used to analyze volumes-of-interest (VOI) on various planar sections 
from the acquired image by manually drawing on the tumor site and on select organs. 
The average VOI was calculated and expressed as % injected dose per gram of tissue 
(%ID/g).  
Antibody Clone Company (Catalog Number) 
HER2 D8F12 Cell Signaling (4290) 
pHER2 (Y1221/1222 6B12 Cell Signaling (2243) 
 
Src 36D10 Cell Signaling (2109) 
pSrc (Y416) D49G4 Cell Signaling (6943) 
 
EGFR-XP D38B1 Cell Signaling (8839) 
pEGFR (Y845) N/A Cell Signaling (2231) 
CD8α D4W2Z Cell Signaling (98941) 
CD3ε D4V8L Cell Signaling (99940) 
GAPDH G-9 Santa Cruz (365062) 
Β-tubulin 9F3 Cell Signaling (2128) 









Imaging Time (h p.i.) 
18F-FDG 150-200 - 1 h 
89Zr-trastuzumab 200-240 66.7-80 48 h 
89Zr-IgG (human) 200-240 66.7-80 48 h 
89Zr-cetuximab 180-200 36-40 48 h 
89Zr-anti-IFNγ 
180-240 42.8 – 57.1 
72 h 
89Zr-anti-CD3 72 h 




64Cu-Ab4 200-240 66.8 - 80 24 h 
Table 20. Tracers and used imaging or antibody doses. 
5.10 Biodistribution 
89Zr-trastuzumab biodistribution was performed 48 h p.i. in BT-474 or JIMT-1 tumor 
bearing Nude mice. To prove specificity, 89Zr-IgG [20-30 µCi, 0.74-1.11 MBq, 336.02-
504.0 nmol, 5-7.5 µg] was injected in mice with BT-474 or JIMT-1 tumors to assess non-
specific accumulation of the tracer. 89Zr-anti-IFNγ biodistribution was performed at 72 h 
p.i. in BALB/c mice, and for blocking studies, 80 μg of cold AN-18 was co-injected with 
the probe in a separate cohort of mice. Select organs were harvested post-sacrifice, 
weighed and measured for bound radioactivity with a gamma counter (Perkin Elmer 2480 
Wizard 2).  
20-30 µCi of the tracer [20-30 µCi, 0.74-1.11 MBq, 336.02-504.0 nmol, 5-7.5 µg] 
was injected into the lateral tail vein. Tissues of interest were removed at indicated 
timepoints and counts were performed using a gamma counter (Perkin Elmer Wizard2). 
The %ID/g was calculated as the % of activity bound to the tissue normalized against total 




5.11 Autoradiography and immunohistochemistry (IHC) 
5.11.1 Autoradiography 
Autoradiography was performed following previously reported protocols(281). 
Briefly, after PET imaging tumors were excised and snap frozen in liquid nitrogen before 
being embedding in OCT medium and cut into 5 µm sections (Leica CM 1850) and 
mounted on positively charged slides (Fisher). Digital autoradiography was performed by 
placing slides in a film cassette against a phosphor imaging plate (Fujifilm BAS-MS2325, 
Fuji Photo Film) at -20 °C for 18 h. Phorphor imaging plates were read at a pixel resolution 
of 25 µm with a Typhoon 7000 IP plate reader (GE Healthcare). 
5.11.2 Frozen immunohistochemistry and hematoxylin and eosin (H&E)  
 Sections were fixed in ice-cold acetone for 10 minutes and dried at room 
temperature for 20 minutes. Endogenous peroxidase activity was blocked with 3% H2O2 
for 10 minutes before blocking with protein block solution from the mouse and rabbit 
specific HRP/3,3’-diaminobenzidine(DAB) detecting IHC kit (abcam, ab64264) for 1 h at 
room temperature. Slides were incubated with primary antibodies for 18 h at 4 °C (Table 
21). Slides were developed using the same HRP/DAB detecting IHC kit and dehydrated 
with alcohols and xylenes before being covered with permount and coverslipped. Imaging 
was performed using a slide scanner (Leica SCN400) and visualized using Leica SCN400 










Table 21. Antibody catalog numbers and dilutions for IHC. 
5.11.3 FFPE Immunohistochemistry and H&E  
After euthanasia, tumors were harvested and fixed in formalin before being 
embedded in paraffin. Blocks were sectioned into 4 µm sections using a Sakura Accu-
Cut SRM microtome (Catalog#: SRM-200 CV) and adhered onto positively charged slides 
(Histomax Plus, VWR). Slides were then incubated for 12 minutes at 65 °C and 
deparrafinized in washes of xylene and graded alcohols. Antigen retrieval was performed 
in PT module buffer (TA-250-PM4X, Fisher) for CD8 (1:200). Primary antibody 
incubations were performed for 1 h at room temperature in a humidified chamber. 
Secondary antibody incubations and DAB were performed following manufacturers 
protocols. CD8 T cell enumeration was conducted by a blinded board-certified 
pathologist. Each tumor sample was screened for hotspots of CD8 lymphocytes using a 
Nikon Eclipse Ci microscope at 100× magnification. The number of CD8+ T lymphocytes 
was counted in the three regions of highest infiltration at 400x magnification with a 0.55 
mm field diameter, and an average was calculated. For H&E staining, tissue sections 
were dipped in xylenes, graduated alcohol and distilled water washes. They were then 
stained with hematoxylin (TA-125-MH, Fisher) for 5 minutes, rinsed with an acid wash for 





HER2 D8F12 4290 1:200 
Src 36D10 2109 1:50 




minute and slides were rinsed in 95% ethanol three times. Lastly, sections went through 
a series of graded alcohol and xylenes steps to dehydrate sections in preparation for 
mounting with Permount (UN1294, Fisher). Pictures were taken with a Spot Idea camera 
using Spot 5.2 software (Spot, Sterling Heights, MI). 
5.12 Quantitative real-time PCR 
Tumor tissue was snap frozen in liquid nitrogen. Total tumor RNA was collected 
by Trizol preparation (Thermo Fisher, Waltham, MA) after homogenization. cDNA was 
synthesized with ProtoScript II reverse transcriptase (New England Biolabs, MA). Real-
time qPCR was conducted with iTaq Universal SYBR Green Supermix (Bio-Rad 
Laboratories, Hercules, CA) using 10 ng cDNA/well and 500 nM primers specific to the 
indicated gene (Life Tech, Carlsbad, CA) (Table 22). Relative mRNA quantities are 
calculated by 2-∆CT compared to GAPDH. 
Target Forward primer Reverse primer 





IFNγ GAGCTCATTGAATGCTTGGC GCGTCATTGAATCACACCTG 
PD-1 CGTCCCTCAGTCAAGAGGAG GTCCCTAGAAGTGCCCAACA 
GAPDH AAGCTCACTGGCATGGCCTTC TGCTTCACCACCTTCTTGATGTC 
Table 22. qPCR primers. 
5.13 ELISA 
Tumor tissue was homogenized in standard RIPA buffer with protease inhibitor 
cocktail (Sigma-Aldrich). Protein concentration was measured by BCA assay 
(ThermoFisher). High protein binding plates (ThermoFisher) were coated with 3 µg/mL 




to 9.0) and washed prior to addition of samples or standard curve using recombinant 
mouse IFN-γ (Peprotech, Rocky Hill, NJ) in duplicate. IFN-γ was detected with biotin-
conjugated anti-mouse IFN-γ clone R4-6A2 (eBioscience), avidin-HRP (ThermoFisher), 
and TMB substrate (ThermoFisher). 
5.14 Serum IgG measurement 
Serum HER2- and neu-specific IgG were quantified by flow cytometry with a BD 
FACSCanto II flow cytometer (Becton Dickinson, Franklin Lakes, NJ), using HER2 over-
expressing SKOV3 cells or neu transfected 3T3/NKB cells as previously described(282). 
Regression analysis was conducted using standard curves of anti-HER2 mAb TA-1 
(Calbiochem, Burlington, MA) or anti-neu mAb 7.16.4 (Calbiochem, Burlington, MA). 
5.15 IFN-γ ELISPOT   
HER2- and neu-specific IFN-γ production was measured by ELISPOT assay as 
previously described(283). Recombinant HER2 or neu (10 µg/mL, Sino Biologicals, 
Beijing, China) were incubated with splenocytes for 48 h in round-bottom wells, followed 
by transfer to anti-IFN-γ coated (clone AN-18, eBioscience) ELISPOT plates (Millipore 
Sigma, Burlington, MA) for an additional 48 h. Spots were detected by biotinylated anti-
IFN-γ (clone R4-6A2, eBioscience) and avidin-HRP (Becton Dickinson, Franklin Lakes, 
NJ), followed by enumeration with an ImmunoSpot analyzer (Cellular Technology Limited, 
Cleveland, OH). Results are expressed as spot forming units (SFU) per 106 cells. 
5.16 Tumor dissociation and flow cytometry 
TUBO tumors from untreated BALB/c mice were dissociated using the 
GentleMACs Dissociator and mouse tumor dissociation kit (Miltenyi, Germany) following 




Table 23. All antibodies/dyes were purchased from eBIoscience (San Diego, CA). 
Samples were analyzed on a BD FACSCantoII flow cytometer (Becton Dickinson, 
Franklin Lakes, NJ) and samples were gated on the viable fraction.  
Antibody Fluorophore Clone 
CD45 FITC 30-F11 
TCRβ APC H57-597 
CD8 PE-Cy7 53-6.7 
PD-1 APC J43 
Viability dye eFluor780  
Table 23.  Flow cytometry antibodies and reagents. 
 5.17 Statistical Analysis 
Statistical analysis was performed using two-way ANOVA test in in vitro assays 
and tumor uptake comparison. An unpaired t-test was used for tumor VOI comparisons. 
A value of P<0.05 was considered statistically significant. Data were expressed as the 





CHAPTER 6. CONCLUSIONS AND FUTURE DIRECTIONS 
The studies described herein encompass three parts including i) examination of 
89Zr-trastuzumab to “monitor the status of Src status after dasatinib treatment in HER2+ 
BC; ii) “Using 89Zr-cetuximab pet imaging to visualize membrane EGFR expression 
following dasatinib treatment in triple negative breast cancer”, and iii) “Using immunoPET 
imaging to monitor tumor response to immunotherapy.” The results are summarized 
below. 
6.1 Conclusions  
In chapter 2, the relationship between Src activation and HER2 was investigated. 
89Zr-trastuzumab was hypothesized to provide a surrogate read out of Src inhibition in 
HER2+ breast cancer. 89Zr-trastuzumab is specific for HER2+ breast cancers. After 
dasatinib treatment in mice bearing BT-474 or JIMT-1 tumors, 89Zr-trastuzumab uptake 
decreased compared to control, untreated tumors, and where standard-of-care FDG-PET 
imaging did not visualize differences in uptake between treated and untreated groups. 
89Zr-trastuzumab tumor uptake correlated with tumor regression and abrogation of pSrc 
(Y416) levels as measured by tumor western blot. 89Zr-trastuzumab can potentially 
assess tumor response to dasatinib in HER2+ breast cancer and could be used as a 
surrogate tool to monitor early changes in Src signaling downstream of HER2. 
 In chapter 3, 89Zr-cetuximab was utilized as a surrogate marker of EGFR 
membrane expression and availability. Upon dasatinib treatment in vitro EGFR localized 
to the plasma membrane, and pSrc (Y416) levels decreased, suggesting dasatinib 
efficacy. 89Zr-cetuximab was specific for high-EGFR expressing TNBC cell lines through 




a lowly EGFR expressing MDA-MB-453 cell line used as an uptake control. After dasatinib 
treatment, EGFR localized to the plasma membrane, where 89Zr-cetuximab binding and 
internalization increased. In tumor models, 89Zr-cetuximab tumor uptake was significantly 
higher in dasatinib treated mice compared to control mice. Interestingly, in KRAS+ MDA-
MB-468 tumors, this translocation was associated with a cetuximab treatment benefit 
when combining dasatinib and cetuximab after imaging, whereas in KRAS-mutant MDA-
MB-231 tumors, there was no cetuximab treatment benefit, which has been observed 
clinically. In conclusion, 89Zr-cetuximab could be used as a marker of EGFR localization 
to predict response to cetuximab treatment, while still keeping KRAS status in mind. 
 In chapter 4, a new immunoPET probe targeting IFN-γ was developmed. Using 
89Zr-IFN-γ PET imaging, active immunotherapy response was visualized, and it was 
concluded that targeting soluble cytokine IFNγ with 89Zr-anti-IFNγ as a read out of 
activated cytotoxic T cells is superior to monitoring TILs with 89Zr-anti-CD3 after 
immunotherapy. In a syngeneic and spontaneous tumor model, 89Zr-anti-IFNγ tumor 
uptake increased after dendritic cell vaccine compared to untreated control, and 
response, as measured by tumor VOI, was correlated with tumor regression. There was 
an increase in CD3, CD8, and IFNγ mRNA after vaccination, an increase in CD8 T cell 
infiltration via IHC after vaccination, and an increase in IFNγ protein as measured by 
western blot. 89Zr-anti-IFNγ PET uptake did not increase above baseline levels in a model 
where T cells have become exhausted and display PD-1. Collectively, IFN-γ PET may 
serve as a non-invasive, comprehensive approach to evaluate tumor immunotherapy. 
6.2 Future directions 




strategy that targets many heterogeneous cancer populations. Currently, breast tumors 
are characterized individually and thoroughly prior to treatment to identify a personalized 
approach to therapy, yet challenges remain in accurate breast tumor subtyping. 
Inaccuracies arise from mistakes in the collection and laboratory processing step, and 
when metastasis has occurred, from the inability to collect samples from every lesion. 
Utilizing immunoPET would meet this need by enabling non-invasive, full body profiling 
of all lesions in the body before, during, and after treatments to tailor each regimen to the 
patient’s tumor load. The studies described in this dissertation have supported this 
hypothesis through imaging response to tyrosine kinase inhibitors and immunotherapies 
alike, and these results provided fundamental insights into the biology of the tumor 
microenvironment, allowing for further refinement of treatment strategies. 
 A promising area of research for BC is through combination therapy. The most 
widely used combination treatments include targeting the PI3K/AKT/mTOR 
pathways(284). For example, the BOLERO study had demonstrated efficacy of combining 
a m-TOR inhibitor and endocrine therapy to restore hormonal sensitivity(284). Palbocib 
(Ibrance®) has been combined with letrozole (Femara®) to treat ER+/HER2- patients in 
the metastatic realm. Trastuzumab has been combined with lapatinib (Tykeb®) or 
pertuzumab (Perjeta®) to treat HER2+ metastatic BCs(284). Many clinical trials have also 
been evaluating the use of combination checkpoint inhibitors, for example combining the 
blockade of CTLA-4 and the PD-1/PD-L1 pathways. Early results have shown an increase 
in efficacy of immunotherapy and slowing of primary tumor growth and metastasis(285).  
 To enhance response rates, a number of studies have suggested combining 




de-addiction and immunomodulation. In EGFR overexpressing TNBC, responses to PD-
1 and PD-L1 antibodies have been dismal, potentially due to the PD1/PD-L1 pathway as 
a mechanism of resistance for EGFR-TKIs. In preclinical studies, mutant EGFR lung 
cancer models treated with anti-PD-1 have demonstrated delayed tumor growth, 
suggesting a synergistic effect between anti-EGFR therapies and anti-PD-L1 in the 
clinic(286). Additionally, PD-1/PD-L1 antibodies have been combined with VEGF blocking 
agents in vivo and resulted in a synergistic anti-tumor effect(287). Currently, a phase II 
clinical trial is recruiting for TNBC (NCT02849496) patients to undergo combination 
atezolizumab (Opdivo®, anti-PD-L1) and veliparib (ABT-888, PARP inhibition) therapy. A 
similar study in small cell lung cancer showed that combining atezolizumab with 
chemotherapy as first line treatment resulted in significantly longer overall survival and 
progression free survival compared to chemotherapy alone. 
 These strategies would allow for disruption of tumor-induced immunosuppression, 
and therefore allow for the immune system to recognize the tumor presence and improve 
the anti-tumor response of checkpoint inhibitors and targeted therapies. In order to 
improve anti-cancer responses, inhibitory molecules would be blocked first to allow the 
immune system to directly attack the cancer. One consideration is the issue of toxicity in 
combining therapies. It would be important to appropriately dose and time treatment 
regimens to achieve high response and low off-target effects, especially since 
immunomodulation typically targets the entire immune system. Additionally, it is important 
that synergy is achieved with combination therapy, and not just two independent 
responses, or one therapy decreasing the targetable population of its partner treatment. 




heterogeneous subtypes of cancer. To achieve this, though, the phenotype of each 
individual BC case should be thoroughly investigated and subtyped before treatment 
allowing researchers and clinicians to gather a general overview of what can be targeted. 
A more precise and personalized characterization of each cancer case and potential 
pathways of resistant on a patient-to-patient basis would be useful in determining 
appropriate treatments. This could include pre-treatment characterization of targetable 
tumor associated antigens (TAAs) (such as PD-1, HER2, or EGFR, for example) through 
IHC, FISH, or immunoPET imaging. Additionally, blood samples for immune cell 
population expression could be used to determine which T-cells to target. Whole genome 
profiling is also of use for prognosis. It is also important during treatment to constantly 
monitor the tumor microenvironment and immune profile to make necessary adjustments 
to combinations, and immunoPET could meet this need. For example, tumors can be 
monitored for expression of targetable biomarkers before treatment in a non-invasive 
way. After treatment has begun, tumors could be re-tested for continuous expression of 
the targeted biomarker, as well as surveillance of expression of known resistance 
pathways. Finally, after a treatment regimen has concluded, tumors can be re-imaged for 
expression of targeted biomarker to see if treatment was successful. Furthermore, we 
have demonstrated that targeted biomarkers can be visualized with various PET tracers, 
allowing for personalized imaging strategies. 
In the final imaging study, panitumumab (Vectibix®) was labeled with 89Zr at a 
target specific activity of 5 mCi/mg. Mice bearing MDA-MB-468 tumors were imaged 
following the scheme outlined in Figure 52A. At 42 h p.i., untreated mice demonstrated a 




(p < 0.001)(Fig. 52B). 89Zr-panitumumab imaged tumors had significantly higher uptake 








Figure 52. 89Zr-panitumumab PET imaging in MDA-MB-468 tumors. Mice bearing 
MDA-MB-468 tumors were treated ith 50 mg/kg dasatinib for 5 d or left untreated before 
undergoing imaging with 89Zr-panitumumab  at 48 h p.i. (A); untreated mice (left) 
demonstrate lower tumor uptake compared to dasatinib treated mice (right) (B); 89Zr-
panitumumab imaged mice demonstrated significantly higher tumor uptake as compared 
to a non-specific isotype IgG (C). 
 
When compared to 89Zr-cetuximab PET imaging, 89Zr-panitumumab imaged 
tumors demonstrated higher uptake (14.8 ± 1.2 %ID/g vs. 8.5 ± 1.7 %ID/g, p < 0.001)(Fig. 
53). This body of work has demonstrated that cell-surface and soluble protein biomarkers 












Figure 53. 89Zr-panitumumab PET imaging compared to 89Zr-cetuximab. Mice 
bearing MDA-MB-468 tumors were imaged with 89Zr-cetuximab (left) or 89Zr-





APPENDIX – INTELLECTURAL PROPERTY 
The information on the 89Zr-α-IFNγPET tracer described in Chapter 4 comprises 
intellectual property of Wayne State University and is covered by a provisional patent filed 
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With a broad spectrum of therapies available for treating breast cancer, the need 
for personalized medicine tailoring the cure according to phenotype is evident. Such an 
approach may be fully realized with the development of quantitative imaging technologies 
for disease detection, staging and diagnosis, without increasing patient burden. Immuno-
positron emission tomography (PET) combines the targeted specificity of antibodies with 
the sensitivity of PET for whole body imaging by targeting molecular features amplified in 
lesions. ImmunoPET probes targeting different antigens and their utility to measure 
response to treatment were explored. 89Zr-trastuzumab was employed as a surrogate 
readout of Src inhibition after dasatinib treatment in HER2+ breast cancer. 89Zr-cetuximab 
was also employed to measure cell-surface EGFR expression following dasatinib 
treatment in triple negative breast cancer. Tumor infiltrating T-cells were measured using 
89Zr-anti-CD3 and 89Zr-anti-IFNγ after vaccination in a murine model of breast cancer. All 
studies utilized in vitro uptake assays, autoradiography, IHC, and western blots to validate 
tracer specificity. PET scans were analyzed after treatment to determine changes in 
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